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Abstract 
Epstein-Barr virus (EBV) is associated with 200,000 cases of cancer per year. Although these 
include B cell lymphomas and epithelial carcinomas, the ability of T cells specific to viral 
antigens to target the latter, which constitute the majority of cases, has not been explored. In this 
study I have investigated the processing and CD4 T cell recognition of epithelial cells expressing 
EBNA1, a virally-encoded protein expressed in all EBV-associated malignancies. EBNA1 was 
equally stable in B cells and epithelial cells but EBNA1-specific CD4 T cell clones were 
nevertheless able to recognise both types of target cell. The potential effects of EBV-encoded 
micro-RNA BART18 on autophagy and CD4 T cell recognition were examined and showed that 
the loss of BART18 increased the autophagy levels of EBV-positive Jijoye Burkitt lymphoma 
cells under nutrient starvation conditions. Finally, the effects of a pharmacological inhibitor of 
EBNA1 dimerisation, JLP2, on the viability and T cell recognition of EBV-positive B cells was 
also investigated.  JLP2 did not increase CD4 T cell recognition but transiently decreased the 
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1.1 T cell Immunology 
Human T lymphocytes (T cells) provide adaptive cellular immunity, protecting the host by 
destroying or suppressing cells that have been infected with a virus or have become cancerous. 
More than 11% of all cancers are associated with viral infections [1] and therefore virus-specific 
antigens are being studied as potential therapeutic targets. 
  
1.1.1 T cells 
T cells are lymphocytes that possess a T cell receptor (TCR) and play a central role in 
controlling virally infected or cancerous cells [2]. The TCR consists of a heterodimer, typically α 
and β chains [3], which associates with a CD3 molecule to form a functional TCR complex. 
During development within the thymus, a T cell will generate a distinct TCR and start expressing 
either CD4 or CD8 [4, 5]. The TCRs are generated through hyper-somatic mutations of the 
variable (V), diversity (D) and joining (J) genes. This process involves the combination of various 
segments from the locus of each of these genes, allowing a large number of possible 
combinations. Because the gene recombination processes occurs in an almost random fashion 
(although not entirely random [6]), a vast diversity of TCRs can be created within the T cell 
population, allowing for the recognition of virtually any non-self antigen. For the β chain of the 
TCR, the D region binds to a J segment followed by a V region. There are also constant domains 
within this formation, which act as hinges and transmembrane regions [7]. The α chain 
recombination follows the same process as the β rearrangement, but without the inclusion of a D 
region. The α and β chains form a heterodimer superdomain that constitutes the peptide-binding 




the binding groove, which is straddled by α-helixes. However, there are important distinctions to 
be made between the CD4 and the CD8 T cells MHC peptide-binding domains that explains 
their functional dichotomy. The peptide-binding site of MHC class I molecules (α1α2) has a 
single polymorphic heavy chain, associated to the light chain sub-unit (β2-microglobulin). This 
closed conformation typically binds peptides that are 8-10 amino acids long. Whereas the 
peptide-binding site of MHC class II molecules (α1β1) has two heavy chains, which creates an 
open ended groove that typically holds peptides of 12 to 20 amino acids in length [8]. T cells are 
activated by short peptides, epitopes, which are displayed by MHC molecules. Normally this 
initial activation will come from antigen presenting cells (APC) [9, 10]. 
  
Subsets of T cells, characterised by the expression of different cell surface markers, have 
different effector functions once activated. Generally, CD8 T cells act as cytotoxic T lymphocytes 
(CTLs) that produce cytokines, such as interferon-γ (IFNγ) and tumour necrosis factor-α (TNF-
α), performing cytolytic activity that can directly kill a target cell. CD4 T cells can be subdivided 
into several subsets based on the expression of effector cytokines. The most studied subset, 
Th1 cells, produce IFNγ, TNF, interleukin-2 (IL-2) and lymphotoxin-α (LTa), which can act to 
stimulate other immune cells such as macrophages and other T cells [11].  Th2 T cells, activated 
by IL-4, provide immunity against extracellular parasites and release effector cytokines such as 
IL-4, IL-10 and IL-13. The Th1-Th2 paradigm provides a simplified framework for the signalling 
molecules and cytokines involved in functional differentiation. However, there is evidence that 
this distinctions in not simply a static relationship. For instance, Th1 cells can be converted into 
Th2 cells upon re-stimulation with IL-4 [12] and Th2 cells can be made to have additional Th1 
function upon IL-12 stimulation [13]. The functional flexibility of CD4 T cell activity is thought to 
arise from genetic plasticity of the differentiation programs [14].  Interestingly, there are a cut-off 




after the cells have undergone a certain number of divisions [12]. There are also certain 
functional transitions that do not occur, such as the conversions from a Th1 or Th2 cell into a 
Treg cell. For the purposes of this work I have purely focussed on Th1 CD4 T cells. Classically, 
CD8 T cells were presumed to control cancer growth. Recently however, the importance of the 
previously overlooked CD4 T cells has become apparent. Multiple reports have demonstrated 
that CD4 T cells exhibit cytotoxic function and have the ability to induce senescence within 
malignant cells [15, 16]. 
  
1.1.2 Generation of T cell epitopes by antigen processing and presentation 
T cells recognise short peptide fragments, termed epitopes, which are bound in the groove of 
MHC class I or MHC class II molecules and displayed on a cell's surface. A crucial factor in 
cellular immunity is the generation and display of epitopes through antigen processing and 
presentation. Proteins within the cytoplasm are continuously being broken down and recycled, 
two main mechanisms involved being proteasomal degradation and autophagy. From both of 
these degradation pathways epitopes are generated, which can then enter into the antigen 
processing pathways [17, 18]. Epitopes bound to MHC molecules are trafficked to the cell’s 
surface for presentation to the immune system. Immunogenic proteins, derived from mutations 
or intracellular parasites, are non-self and therefore elicit an immune response upon 
presentation. This process allows T cells to selectively eliminate the cancerous or virus infected 
target cells. MHC class I molecules are recognised by CD8 T cells and are expressed by almost 
all nucleated cells. In contrast, MHC class II molecules are recognised by CD4 T cells and, 
whilst it was initially thought that MHC class II was limited to subsets of specialised APCs, they 
are now known be expressed on a wide range of cells given the appropriate conditions. For 
example, exposure to certain inflammatory cytokines, such as IFNγ, activates the MHC class II 




[19]. Therefore, numerous cell types are potentially visible to CD4 T cells, especially within the 
inflammatory tumour microenvironment. 
  
The classical model for antigen processing and presentation states that endogenous proteins 
are processed by the proteasome and presented by MHC class I, while exogenous proteins are 
endocytosed and then presented by MHC class II. However, this simplified model has had to be 
revised following two important observations: i) exogenous proteins can be processed and 
presented via MHC class I (e.g. cross presentation by dendritic cells) [20] and ii) endogenous 
proteins contribute to a significant proportion of the epitopes presented by MHC class II (e.g. 
proteins processed by autophagy) [21]. 
  
1.1.3 Antigen processing and presentation by autophagy 
One of the main routes allowing intracellular proteins to gain access to the MHC class II 
processing pathway is macroautophagy (hereafter referred to as autophagy). This pathway is an 
evolutionarily conserved homeostatic mechanism in eukaryotes by which old or damaged 
proteins are degraded and recycled [22]. The highly coordinated process of autophagy involves 
the formation of a double membrane, known as an autophagosome, around cytosolic cargo, 
which is then transported to lysosomes for degradation [23]. In most cells a low basal level of 
autophagy is maintained. However, in times of cellular stress, such as nutrient deprivation, it is 
upregulated to postpone the cell’s death from starvation. Autophagy was initially thought to be a 
non-selective pathway, but more recent evidence suggests that distinct microstructures are 
directly targeted for destruction [24]. Importantly for the present study, intracellular proteins that 
are degraded by autophagy gain access to the MHC class II processing pathway through the 
MHC class II loading compartments (MIICs), as evident from the several autophagy dependent 




antigen presentation is seen upon activation of autophagy by starvation [21]. Furthermore, fusing 
together a target antigen with LC3, an autophagy protein that localises to the autophagosome, 
dramatically increases the levels of MHC class II presentation and CD4 T cell recognition [26, 
27]. Autophagy therefore provides an important mechanism for pathogenic proteins to be 
endogenously processed and presented to CD4 T cells. 
  
1.1.4 Immunology and immunotherapy of virus-associated malignancies  
Cells that have become cancerous or infected with viruses can be controlled by adaptive 
immune surveillance, such as T cell recognition of immunogenic epitopes [28, 29]. Virus-
associated malignancies can arise when the immune system is suppressed, but they can also 
develop in people who are not overtly immunosuppressed. Oncogenic viruses, such as EBV and 
HPV, have co-evolved with humans and have developed immune evasive tactics, helping the 
infected cells avoid immune detection [30]. As oncogenic viruses account for over 11% of all 
malignancies [1], there is considerable interest in targeting viral epitopes, which are not present 
in normal tissue, for treating these cancers. 
  
Recently, the immunotherapy of cancer has progressed with the development of several 
clinically effective treatments. These include; immune checkpoint blockade, such as ipilimumab, 
and passive cellular immunotherapy, such as adoptive T cell transfer. Administering T cells, 
which have their own immunological activity, offers a therapy to patients that may not have fully 
functional immune system themselves [31]. It is well known that CD8 T cells are effective for 
antitumour immunity, while CD4 T cells have generally been overlooked as only providing a 
support role for sustained immune response [32]. However, recent evidence has shown that 
CD4 T cells are able to provide effector function and induce senescence in tumour cells [16]. 




(PTLD) patients, in which a positive correlation was shown between an increased CD4:CD8 T 
cells ratio and improved patient outcome [33]. Further evidence for the importance of CD4 T 
cells comes from melanoma, where CD4 T cells were able to clear tumours resistant to CD8 T 
cells in a mouse model [34] and administering CD4 T cells was able to completely eradicated 
tumours in patients [35]. Although previously overlooked, CD4 T cells clearly have considerable 
potential to enhance the efficacy of cancer immunotherapies. In this regard, viral malignancies 
provide a valuable model system in which to develop novel immunotherapeutic strategies. The 
fact that the virally encoded tumour antigens are completely restricted to only the tumour cells 
minimises the risk of dangerous off target immune responses. Furthermore, because the target 
antigens are non-self, this means that the T cell responses are typically of a higher avidity 












1.2 Epstein-Barr virus 
Epstein-Barr virus (EBV) is a DNA tumour virus that has co-evolved with the human species for 
millions of years and infects over 90% of adults worldwide [36]. As a lifelong herpesvirus 
infection, EBV normally persists asymptomatically due to effective control by T cell surveillance 
[37]. The initial oral transmission of EBV leads to a primary infection of epithelial cells within the 
oropharynx where the virus enters a lytic phase, replicating in vast quantities. The latent phase 
of EBV infection, mainly found in memory B cells and certain epithelial types, involves the 
persistence of the viral episome without active viral production [38]. Different latency stages are 
characterised by various patterns of virally-encoded miRNA and latent gene expression [39]. 
  
1.2.1 EBV-associated cancers 
The transformative properties of EBV’s latent protein expression act synergistically with 
tumorigenic traits that may develop within a host cell. For example, LMP1 and LMP2  are 
responsible for enhancing cell proliferation programs and EBNA1 has been shown to enhance 
tendencies for cell immortalisation [40] [41]. EBV infections are associated with around 200,000 
malignancies worldwide every year [42]. In B cell lymphomas, EBV is associated with 45% of 
Hodgkin's lymphoma (28,000) and 90% of Burkitt's lymphoma (6,600) cases within endemic 
areas. However, the majority of cases are found in the epithelial cancers where EBV is 
associated with around 10% of gastric carcinoma (84,000 cases) and 97% of nasopharyngeal 
carcinoma (NPC) (78,000) cases. Targeting a viral antigen common to all these diseases may 
therefore offer a universal treatment option for these patients. 
 
T cells play an important role in controlling EBV infections and mitigating the development of the 
associated cancers. This is highlighted by evidence from patients who are immunosuppressed 




the removal of T cell surveillance, leading to the uncontrolled proliferation of EBV infected B 
cells. Recently, clinical trials have shown successful results from EBV-specific immunotherapy. 
In a Phase II clinical trial, 14 out of 33 PTLD patients made a complete remission after receiving 
adoptive T cell therapy [33]. This paper also demonstrated that improved outcomes could be 
achieved with a higher CD4:CD8 T cells ratio and by appropriating closer HLA matched donors. 
Another example of an EBV targeted immunotherapy of cancer is a poxvirus vaccine currently in 
phase II testing, delivering a LMP2-EBNA1 fusion protein designed to stimulate autologous T 
cells against latent EBV-associated NPC [43]. Potentially, improvements could be made in the 
field of immunotherapy by better understanding the utility of different T cell phenotypes and EBV 
antigen presentation, in order to find the most appropriate effectors and universal target on 





1.3 Epstein-Barr virus nuclear antigen 1 
The expression of EBV nuclear protein antigen 1 (EBNA1) is seen in 100% of EBV-associated 
malignancies, as it has vital roles in maintaining the viral episome during cell division [44]. It is 
now known that intracellular processing results in MHC presentation of epitopes, which elicits 
responses from CD4 and CD8 T cells [45, 46]. However, a definitive mechanism explaining the 




The endogenous stability of EBNA1 has mainly been studied in EBV infected B cells, known as 
lymphoblastic cell lines (LCLs), in which EBNA1 has a very long half-life. Autophagy has been 
suggested as one of the mechanisms for the low levels of degradation that do occur. Evidence 
for this comes from the inhibition of lysosomal acidification, which results in the accumulation of 
EBNA1 in cytosolic autophagosomes and reduces CD4 T recognition levels of certain MHC 
class II EBNA1 epitopes [25]. 
  
Interestingly, the one study that has examined the stability of EBNA1 in another cell type, 
epithelial cells, reported that its half-life was much shorter (Figure 1.3.1) [47]. The half-life of 
EBNA1 was measured in B cells and epithelial cell lines (transiently transfected with a plasmid 
encoding EBNA1) by inhibiting protein synthesis with cycloheximide and measuring the level of 
EBNA1 over time. As expected, the half-life of EBNA1 in B cells was very long, greater than 30h. 
However, EBNA1 was degraded rapidly in epithelial cell lines; the half-life was calculated to be 
around 4h in the HaCaT cell line and 20–24h for SVMR6 and HEK293 cell lines. The half-life of 
EBNA1 was not affected by removing the glycine/alanine repeat (GAr) domain sequence 




cell recognition). This work raises some interesting questions regarding MHC class II processing 
of EBNA1, which have not yet been explored within the literature, such as the mechanism 
responsible for the enhanced degradation seen in cell types other than B cells. This mechanism 
could potentially be autophagy, which would supply EBNA1 peptides to the MHC class II 
processing pathway, perhaps making EBV-associated epithelial malignancies excellent targets 
for CD4 T cells. This knowledge could have potential applications for the immunotherapy of 
EBV-associated epithelial malignancies. 
  
1.3.2 Endogenous processing and presentation 
Although there is no consistent intracellular processing route for the MHC class II antigens of 
EBNA1 [36, 48], the presentation of several epitopes has been shown to be autophagy 
dependent [25, 49]. A study by Leung and colleagues demonstrated that only two (SNP and 
VYG) out of the three CD4 T cell clones tested against LCLs could recognise their target and 
that only one of these epitopes (SNP) was dependent on autophagy for presentation [45]. The 
overexpression of EBNA1 did not alter the processing route, but the relocalisation of EBNA1 to 
the cytoplasm resulted in all three of the epitopes being processed effectively by autophagy. 
This work demonstrates that the natural nuclear location of EBNA1 benefits the protein by 
conferring protection from autophagic degradation and consequently limiting CD4 T cell 
recognition. 
  
1.3.3 T cell recognition of latent antigens 
CD8 T cell recognition of EBNA1 is limited by the small number of MHC class I epitopes present 
in the protein [36, 50]. Comparatively, CD4 T cells are able to recognise a wide range of EBNA1 
epitopes presented by MHC class II. The Th1 CD4 T cells that respond to EBNA1 epitopes are 




Many EBV-associated malignancies are capable of expressing MHC class II molecules, 
including Burkitt's lymphoma (which actually lacks MHC class I) and even the epithelial cells 
associated with EBV infection, which can typically upregulate MHC class II expression in the 
presence of cytokines that are present in the inflammatory tumour microenvironment. It is 
therefore vital to study the novel area of CD4 T cells controlling EBV-associated epithelial 
malignancies. 
  
1.3.4 Inhibition of EBNA1 function 
Another complementary therapeutic strategy to treat EBV-associated malignancies is the 
inhibition of EBNA1, which is essential for the maintenance of the viral episome and is 
expressed in all EBV-associated malignancies. Mutant dominant-negative EBNA1 proteins affect 
EBNA1 processing and increase the levels of epitope presentation by MHC class I, thereby 
enhancing T cell recognition [52]. However, the logistics of using dominant-negative proteins as 
a therapeutic treatment is technically challenging [53] and a simpler approach may be to utilise 
pharmacological inhibitors of EBNA1 dimerisation. Peptides that bind specifically to the EBNA1 
dimerisation domain are selective agents that inhibit EBNA1 function and, through removal of 
the EBV episome, could also help induce cell death of EBV infected cells. It is not known 
whether these drugs will also affect the processing and presentation of EBNA1. Several 
advancements have recently been made in the development of such an EBNA1 inhibitor that 
could potentially be used to treat EBV-associated malignancies [54, 55]. 
  
JLP2 is an EBNA1 specific probe, designed using molecular computation to inhibit EBNA1 
dimerisation [55]. The presence of the JL chromophore allows the molecule to be visualised with 
a confocal microscope and fluorescence levels quantified with flow cytometry. Upon binding to 




EBV and non-EBV infected cells. In vitro, the treatment of an EBV-positive NPC cell line, in 
comparison to treatment of an EBV-negative cell line, with JLP2 allowed for selective 
visualisation and induced a dose dependent decrease in cell viability [55]. As there may be 
clinical use for a pharmacological inhibitor of EBNA1 in the immunotherapy of EBV-associated 
malignancies, it is worth exploring the effect of JLP2 in different cell types and to determine 








Figure 1.3.1 Variable half-life of EBNA1 in epithelial cell lines 
A) A schematic map of EBNA1 and EBNA1ΔGA expression constructs (B) Intracellular half-life 
of transfected EBNA1/EBNA1ΔGA in different cell types. After the addition of cycloheximide 
(50μg/ml) EBNA1 was chased for 30h and expression levels were measured using western blot. 
DG75 (B cell) shows EBNA1 to be incredibly stable over 30h. However, HEK293 epithelial cells, 
SVMR6 keratinocytes and HaCaT keratinocytes all have a much shorter half-life for EBNA1. 






1.4 Aims of this project 
The aim of this project was to explore the processing and presentation of the ubiquitously 
expressed EBV-encoded EBNA1 protein in the context of epithelial cancers. To achieve this, the 
half-life of EBNA1 was assessed and the CD4 T cell recognition of several epithelial cell lines 
was measured. This project also aimed to explore the manipulation of CD4 T cell recognition 
through the application of an EBNA1 dimerisation inhibitor (JLP2) and through the knockout of a 
specific EBV-encoded miRNA (BART 18), postulated to suppress autophagy levels. The work 
here was designed to gain further insight into the utility of EBNA1 specific CD4 T cells, with the 
long term aim of developing immunotherapeutic options for patients with EBV-associated 










2. Materials and methods 
 
2.1 Cell lines   
 
2.1.1 Table of all the adherent cell lines used in the study   
Cell line  Cell type  Source  Split ratio 
MKN1 Gastric carcinoma  Chris Dowson (1)  1:5 
MKN28 Gastric carcinoma Chris Dowson   1:5 
MKN45 Gastric carcinoma Chris Dowson  1:5 
NUGC4 Gastric carcinoma Chris Dowson  1:3 
SNU  Gastric carcinoma Chris Dowson  1:3 
HeLa Epithelial   Graham Taylor (1)  1:6 
293FT  Epithelial Leah Fitzsimmons (1)  1:8 
HaCaT Karanocyte  Graham Taylor  1:6 
MJS Melanoma  Graham Taylor  1:8 
MJS EV 
overexpression  
Melanoma Marjolein Hooykaas (2) 1:5 
MJS B16 
overexpression 
Melanoma Marjolein Hooykaas 1:5 
MJS B18 
overexpression 
Melanoma Marjolein Hooykaas 1:5 
MJS C1 
overexpression  
Melanoma Marjolein Hooykaas 1:5 
 
Key:  
1) University of Birmingham  










2.1.2 Table of all the B cell lines used in the study   
Cell line Cell type Source  Split ratio 
LCL (GT) EBV+ B cell Graham Taylor (1) 1:2 
LCL (GS) EBV+ B cell  Graham Taylor  1:2 
Akata  EBV- B cell  Alison Leese (1) 1:3 
Awaia  EBV- B cell Alison Leese  1:3 





Jijoye B16 k/o EBV+ Burkitt's 
lymphoma 
Marjolein Hooykaas 1:2 
Jijoye B18 k/o EBV+  Burkitt's 
lymphoma 
Marjolein Hooykaas 1:2 
   
Key:  
1) University of Birmingham  
2) University of Leiden 
 
Lymphoblastic cell lines (LCLs) provided by the lab were B cells previously immortalised through 










2.2.1 Table of reagents  
Reagents  Details Storage  Manufacturer  
RPMI (media) RPMI-1640 supplemented with 0.2M L-
glutamine  
4°C Gibco 
FCS Foetal calf serum (FCS)  -20°C Gibco  
pen/strep Penicillin-streptomycin  (5000IU/ml 
penicillin and 5000µg/ml streptomycin 
solution) 
4°C Gibco 
Opti-MEM Reduced-Serum Medium 4°C Life technologies 
PBS Phosphate buffered saline solution (1 PBS 
tablet/100ml SDW) 
RT Oxoid   
PBS Tween  PBS + Tween (0.5ml/L for ELISA, 1ml/L 
for Western blot)  
RT Dulbecco  
Dox Doxycycline (100µg/ml) dissolved in 
DMSO 
4°C Sigma  




Lipofectamine Lipofectamine 2000 4°C Life technologies 
Mirus  Mirus Transit X2 4°C Mirus bio 
Propidium 
Iodide  
 RT  Life technologies 
WST-1  -20°C Roche 
IFN-γ Recombinant IFN-γ -20°C Peprotech 
TMB  4°C Oxoid  
ExtrAvidin- 
Peroxidase  
 4°C Life technologies  
Coating buffer 12mM Sodium carbonate and 74mM 





Blocking buffer PBS-Tween (BSA)   4°C  
Run buffer 250mM Tris,1.9M Glycine and 1% SDS RT  
Sample buffer  62.5mM Tris pH6.8, 4% SDS and 0.01% 
Bromophenol blue,  
4°C  
Urea buffer 9M Urea and 50mM Tris pH7 RT  
JLP1  5mM JLP1 dissolved in DMSO -20°C  
JLP2 JLP2 5mM dissolved in DMSO -20°C  
 
2.2.2 Table of kits  
Kit Details Storage  Manufacturer  
BCA protein assay kit  Reagents A:B (20:1) 4°C Thermoscientific  
ECL western blot detection 
reagents  
Reagents 1:2 (1:1)  4°C GE healthcare  
 
2.2.3 Table of antibodies  
Detection Primary  Secondary  Technique  
EBNA1 (50-70kDa) 1H4 (1:50) Anti-Rat (1:000)  Western blot  
LC3-II (14kDa) LC3 (1:3000) Anti-Goat (1:000)  Western blot  
Cyclin E (53kDa) Cyclin E (1:300) Anti-Goat (1:000)  Western blot  
Cyclin D2 (34kDa) Cyclin D2 (1:300) Anti-Goat (1:000)  Western blot  
BIP (64kDa) BIP (1:1000) Anti-Rat (1:000)  Western blot  





MHC class I  Anti-Human HLA-ABC NA Flow cytometry  
MHC class II  Anti-Human HLA-DR  NA  Flow cytometry  
 
All antibodies were stored at -20oC. The western blot antibodies were diluted (ratios given in 





2.2.4 Plasmids  
All plasmids used for the transfection of adherent cell lines had been previously developed within 
the laboratory (G. Taylor, University of Birmingham) and were built upon a pCDNA3 backbone. 
These induced: EBNA1 constructs, HLA-restriction genes, and a GFP plasmid. The various 
EBNA1 constructs, E1ΔGA, E1ΔNLSk/o and IiE1Δ, each possessed different capabilities of 









Figure 2.2.1 Schematic of EBNA1 constructs 
A schematic map of the various EBNA1 constructs, which had previously been incorporated into 
a pCDNA3 vector for use in transient transfection. A full length EBNA1 is shown at the top with 
annotated locations of GAr and two MHC class II-restricted epitopes, SNP and VYG. E1ΔGA, 
which has the GAr repeat entirely deleted, is shown below. Next, E1ΔNLSk/o is shown to be 
identical to E1ΔGA except for the mutation of 3 amino acids within the nuclear localisation 
sequences (resulting in a cytoplasmic-localised EBNA1). Finally the IiE1Δ is shown, which is 
identical to the E1ΔGA apart from the addition of an invariant chain sequence (amino acids 1-80) 
to the amino terminal end of the protein (resulting in effective transport of EBNA1 into the MHC 





2.3 Techniques  
 
2.3.01 Cell culture  
All cell lines were cultured (37oC 5% CO2) in T75 flasks (Corning) and passaged twice a week 
depending on confluence (see Table 2.1.1 for split ratio). All adherent cell lines were cultured in 
RPMI 10% FCS and 1% pen/strep. All non-adherent (B cell) lines were cultured in RPMI 10% 
FCS. All adherent cell lines were passaged by removing media from the flask, washing twice 
with 6ml PBS and adding 1ml of trypsin for 5-10 minutes (37oC 5% CO2). Loose cells were then 
suspended in fresh media and split in the same way as non-adherent cells by passaging the 
cells at the required ratio.    
 
2.3.02 Fluorescent microscopy  
The same area of cells was visualised (80x) using a microscope (Evos) under bright field and 
UV.  
 
2.3.03 Lentiviral transduction  
Adherent cells (2x105) were cultured (37oC 5% CO2) in 6 well plates for 24h. The infectious 
lentiviral supernatant (harvested from lentivirus construction in 293FT cells) and polybrene 
(6µg/ml) were added to the cells, which were then incubated (37oC 5% CO2) for 30 minutes. The 
plate was then centrifuged (2,200rpm) for 2h at 32oC. The supernatant was removed from the 
cells, which were then washed twice with 2ml of PBS. Fresh media was added and normal 
culturing was resumed. The lentiviral gene integration was assessed by measuring the levels of 






2.3.04 Transient transfections  
 
2.3.04.1 Lipofectamine 2000 transfection  
Adherent cells (6x105) were cultured (37oC 5% CO2) in 6 well plates for 24h (typically reaching 
80% confluency before the transfection). Lipofectamine (5µl/well) was mixed with pre-warmed 
opti-MEM (150µl/well) for 5 minutes (room temperature). DNA (various possible concentrations 
0.2-4µg/ml) was then combined with the lipofectamine and additional opti-MEM (150µl/well). 
This transfection solution was incubated (room temperature) for 25 minutes. The media within 
the 6 well plates was replaced by 200µl/well opti-MEM and 300µl/well of transfection solution. 
The cells were then incubated (37oC 5% CO2) for 4h (rocked every 30 minutes). The transfection 
solution was then replaced with fresh media and the transfected cells were cultured for 2-3 days 
before use. (The volumes of transfection reagents were adjusted accordingly for larger or 
smaller well sizes) 
 
2.3.04.2 Mirus TransIT-X2 transfection 
Adherent cells (3x105) were cultured (37oC 5% CO2) in 12 well plates for 12h (typically reaching 
80% confluency before the transfection). DNA (1µg/well), TransIT-X2 (3µl/well) and pre-warmed 
Opti-MEM (250µl/well) were mixed and then incubated (room temperature) for 30 minutes. 
250µll of this transfection solution was pipetted gently onto the cells (without removing the 
original media) and the plates were rocked to achieve even distribution. The cells were cultured 
(37oC 5% CO2) for at least 24h before use.  
 
2.3.05 LC3 flux  
The cell lines were cultured (37oC 5% CO2) in four wells of a 6 well plate for 24h. The media was 




other two. For both serum conditions, one of the two wells was treated with bafilomycin A1 
(100nM). After 6h incubation (37oC 5% CO2) the cells were harvested and washed twice in PBS 
(5ml). After the final centrifuge (1500rpm for 5 minutes) the PBS was removed using a p1000 
pipette and the cell pellet was stored (-80oC) until use in western blots.  
 
2.3.06 Protein stability assay  
Adherent cells were cultured in four wells of a 6 well plate for 48h after transient transfection with 
an EBNA1 plasmid. Cycloheximide (50µg/ml) was added to the wells and the cells were chased 
for 0, 4, 8 or 24h. The cells were harvested and washed twice in PBS (5mls). After the final 
centrifuge (1500rpm for 5 minutes), the PBS was removed using a p1000 pipette and the cell 
pellet was stored (-80oC) until use in western blots.  
 
2.3.07 SDS-PAGE and western blotting  
The cell pellet was suspended in urea buffer (1µl per 1x104 cells) and sonicated (Qsonica) at 
30% for 10 seconds. The sample was then centrifuged at 13,000rpm for 20 minutes (4oC). The 
supernatant was transferred to a sterile eppendorf (1.5ml) and protein concentration was 
determined using a BCA protein assay. The standardised samples were combined with 2X Gel 
Sample Buffer and β-mercaptoethanol (1:20µl) within a fume hood. The tubes were heated to 
100oC for 5 minutes on a heat block before the samples were loaded onto an Any kD Precast 
Gel (Bio-Rad) and run at 100-150V for 1-2h. In some cases a ChemiDoc (Bio-Rad) was used to 
analyse the protein loading of the gel. The protein was then transferred from the gel onto a 
nitrocellulose membrane (Midi Trans-Blot Turbo transfer pack (Bio-Rad)) using a Trans-blot 
Turbo Transfer system. The membrane was then blocked with milk (5% milk in PBS-Tween) for 
1h. The relevant primary antibody (see Table 2.2.3) was then incubated (4oC) with the 




room temperature) four times in PBS-Tween and then the secondary antibody incubated (room 
temperature) with the membrane on a 3D rocker for 1h. The membrane was washed (10 
minutes on a 3D rocker at room temperature) four times in PBS-Tween and then treated using 
the ECL kit (for western blot detection), after which the film was exposed to the membrane within 
a cassette. The film was developed using an automatic film developer, then the protein ladder on 
the membrane was aligned and marked onto the film. In some cases, after ECL treatment a 
ChemiDoc was used as an alternative to film development to measure the band intensities.  
 
2.3.08 BCA protein assay  
Protein lysate samples were diluted (1:2 and 1:4) using urea buffer and 20µl was added in 
duplicate to a 96 flat bottom plate. A protein standard (BSA 2-0.125mg/ml using half dilution 
method) was then added to the 96 flat bottom plate, also in duplicate. The WR reagent was 
prepared (50:1 A:B regents from BCA kit for protein assays) and 200µl/well was added to the 
plate. The plate was incubated (37oC 5% CO2) for 30 minutes. Absorbance (550nm) was then 
measured using a plate reader. The protein standard curve allowed the protein concentration for 
each sample to be determined. The original samples were then standardised (diluted using urea 
buffer) to the equivalent protein concentrations for use in SDS-PAGE.   
  
2.3.09 MHC class I and II staining  
Each cell line was cultured (37oC 5% CO2) for 3 days in two T25 flasks; one with IFNγ (10-
100ng/ml) and the other left untreated. The cells were harvested by trypsinisation and 
resuspended in PBS (1% FCS). The cells were split (4x105) into three FACS tubes, centrifuged 
(1,750rpm) and, with the supernatant removed, incubated (37oC 5% CO2) for 30 minutes. One of 
the FACS tubes was treated with 20µl of the MHC class I specific antibody (antihuman (W6/32) 




(L243) HLA-DR) and the third FACS tube was left untreated. The cells were incubated on ice for 
60mins (flicked every 20mins), washed twice in 3mls PBS (1%FCS) and finally resuspended in 
200µl of PBS for use in flow cytometry. The levels of surface MHC presentation were measured 
using flow cytometry (FL-4) as the antibodies were conjugated to APC. 
 
2.3.10 Propidium iodide staining 
The control, containing both dead (freeze thawed) and living cells, was prepared. After adding 
propidium iodide (life technologies) to each of the controls and the samples (to make a final 
concentration of 3µM), the cells were immediately analysed using flow cytometry (FL-3). The 
gating around the living and dead cells in the control allowed accurate assessment of viable cells 
within each sample.    
 
2.3.11 Flow cytometry 
Cell samples (suspended in PBS) were vortexed before being analysed with a flow cytometer 
(Accuri C6). The number of cells used, FL measurement and gating depended on the specific 
experiment.  
 
2.3.12 T cell assay  
T cells (5x103/well) were incubated (37oC 5% CO2) with target cells (5x104/well) in a 96 well 
round bottom plate with 200µl RPMI (10% FCS) for 12h. The supernatant was harvested and the 
IFNγ levels were measured using an ELISA. 
 
2.3.13 ELISA  
A flat bottom 96 well Coat MaxiSorp plate (Nunc) was coated with anti-human IFNγ capture 




the plate was blocked with blocking buffer (200µl/well) for 1h. The plate was washed (with PBS-
Tween) six times and then the standards (50µl/well, ranging from 4000–68.5pg/ml) and 
supernatant samples (50µl/well) from the overnight T cell assay were added to the plate (in 
triplicate). The plate was incubated at room temperature for 4h and then washed six times (with 
PBS-Tween). Biotin-labeled anti-human IFNγ (50µl/well) was diluted (1/1333) in blocking buffer, 
added to the plate and incubated (room temperature) for 2h. The plate was washed six times 
(with PBS-Tween). ExtrAvidin-Peroxidase (50µl/well) was diluted (1/1000) in blocking buffer and 
added to the plate, which was then incubated (room temperature) for 30min. The plate was 
washed eight times (with PBS-Tween) before adding TMB substrate (100µl/well) for 20 minutes 
to allow for colour development. The reaction was stopped using 1M HCL (100µl/well). The 
absorbance (450nm) of the samples was assessed using a plate reader. The IFNγ standard 






3.1 Endogenous stability of EBNA1 
Cell lines were chosen that have physiological relevance to EBV-associated epithelial 
malignancies, in which to study the endogenous stability of EBNA1. Several gastric carcinoma 
cell lines were selected; MKN1, MKN28, MKN45 and NUGC4. Additionally, various model cell 
lines were also chosen based on their use in previous studies; 293FT (epithelial) and HaCaT 
(Keratinocyte, specialised epithelial) cell lines that had been used to report the low stability of 
EBNA1 and HeLa (epithelial) and MJS (melanoma) cell lines that had been used for the study of 
antigen processing and presentation. The MKN28 cell line was natively EBV-positive and 
therefore expressed physiological levels of EBNA1. In order to study the endogenous stability of 
EBNA1 in the various cell lines, I decided that it would be worthwhile spending the time and 
resources to establish an inducible EBNA1 expression system, in which physiological or indeed 
supraphysiological levels of EBNA1 could be generated on demand. 
  
3.1.1 Lentiviral transduction of epithelial lines with EBNA1 
A lentiviral transduction system was chosen to generate stable cell lines with a heritable EBNA1 
gene incorporated into the host cells’ genome. The lentiviral system I selected had been 
previously developed and optimised for the transduction of B cells (L. Fitzsimmons, personal 
communication). The lentiviral construct consisted of an inducible full length EBNA1 and a 
constitutively expressed GFP gene. The infectious lentivirus was produced in 293FT cells, 






To determine whether the lentiviral genome had been stably incorporated into the cell lines, 
microscopy (Figure 3.1.1) and flow cytometry (Figure 3.1.2) were used to assess GFP 
expression 21 days after transduction. A high proportion of cells were successfully transduced 
for the MKN1 (96.1%) and MKN28 (86.9%) cell lines, with lower levels seen in the MKN45 
(60.9%), HaCaT (50.0%) and Hela (31.9%) cell lines. 
  
To assess the amount of protein expressed from the inducible EBNA1 gene, a doxycycline (dox) 
titration was performed on the lentivirus transduced MKN1 cell line. The MKN1 cells were 
cultured with dox (0, 10, 20, 50, 100 or 200ng/ml) for 48h. The cells were then harvested and the 
protein levels standardised. The EBNA1 protein levels were measured using a western blot 
(Figure 3.1.3). The inducible EBNA1 gene was seen to be expressed in the absence of dox and, 
although the cells had been effectively transduced, high doses of dox only induced low levels of 
EBNA1 expression. This inducible expression of EBNA1 was low in comparison to the levels 
seen in lentiviral transduced B cells or even physiological levels seen in naturally EBV-positive 
cell lines, such as LCL and MKN28 cells (data not shown). 
  
Although EBNA1 expression was only inducible to low levels a stability assay was attempted, 
measuring the natural degradation of EBNA1 in the lentivirus transduced cell lines (MKN1 and 
MKN28). The cells were treated with dox (200ng/ml) for 48h to induce EBNA1 expression. 
Protein synthesis was then inhibited with the addition of cycloheximide (50µg/ml) and cells were 
chased for 0, 4, 8 or 24h. Protein levels were standardised and EBNA1 levels were assessed 
using a western blot (Figure 3.1.4). Despite the low expression of EBNA1, the consistent bands 
seen over 24h, in both MKN1 and MKN28, suggested that the full length EBNA1 was stable and 
not subject to degradation. Although the other lentivirus transduced cell lines were tested several 





The reason for the low inducible EBNA1 expression in the lentivirus transduced epithelial cells 
was not investigating further. Instead, an alternative method of expressing EBNA1 in epithelial 








Figure 3.1.1 Visualisation of GFP expression in lentivirus transduced epithelial cell lines 
Fluorescent microscopy was used to examine cell lines (MKN1, MKN28, MKN45 and NUGC4) 
transduced with lentivirus expressing the inducible EBNA1 and constitutive GFP gene, 21 days 
after the transduction. The same field of cells was visualised with bright field (left column) and 
UV light (right column) in order to detect GFP expression. Various levels of GFP expression 








Figure 3.1.2 Analysis of GFP expression in lentiviral transduced epithelial cell lines 
Flow cytometry analysis of non-transduced (black line) and lentivirus transduced (red line) cell 
lines (MKN1, MKN28, MKN45, Hela and HaCaT) was used to quantify the populations of cells 
expressing GFP (M4/M2 set at FL1>99% of non-transduced cells; value provided as a 
percentage in each panel). Intact cells were analysed by gating on this population using forward 










Figure 3.1.3 Assessment of inducible EBNA1 expression in lentiviral transduced MKN1 
cell line 
Western blot analysis of EBNA1 expression levels in the lentivirus transduced MKN1 cell line. 
Cells were treated with doxycycline (titrated between 0-200ng/ml) for 72h to induce the 
expression of EBNA1 (lentivirus incorporated gene) before harvesting. The protein levels were 
standardised and EBNA1 levels were assessed by western blotting. The inducible gene was 
seen to express low levels of EBNA1 in the absence of doxycycline, whilst treatment with high 








Figure 3.1.4 Analysis of induced EBNA1 stability in lentivirus transduced epithelial cell 
lines 
Lentivirus transduced cell lines (MKN1 and MKN28) were treated with doxycycline (200ng/ml) for 
48h, to induce the expression of EBNA1. The protein synthesis was then inhibited using 
cycloheximide (50µg/ml) and cells were chased for 0, 4, 8 and 24h. The protein levels were 
standardised and EBNA1 levels were assessed by western blotting. No changes in EBNA1 
levels were observed across the 24 hours, indicating high levels of stability in both of the gastric 











3.1.2 Transient transfection of epithelial cells with EBNA1 
Rather than pursuing the lentiviral system in which inefficient levels of inducible EBNA1 were 
expressed by the transduced epithelial cell lines, I decided to use an alternative system utilising 
transient transfections to explore the key question of EBNA1 stability. Two reagents, 
Lipofectamine 2000 (Lipofectamine) and Mirus Transit X2 (Mirus), were compared in order to 
determine which was most appropriate for the transfection of a range of epithelial cell lines 
(MKN1, MKN28, MKN45, NUGC4, HeLa, 293FT and HaCaT). Both reagents were used in 
accordance with the manufacturer's protocol for the transfection of all cell lines with a plasmid 
encoding GFP expression (pCDNA3-GFP). Flow cytometry was used to quantify transfection 
efficiency (GFP expression) and cell viability (propidium iodide staining), comparing transfected 
cells to mock transfected control cells of the same type (Figure 3.1.5). The cell viability for 
Lipofectamine transfected cells was consistently better than, or as good as the results from 
Mirus transfected cells. For transfection efficiency, the pattern varied between the two reagents 
depending on the cell line. However, the three fold increase seen for two gastric carcinoma cell 
lines, MKN1 and MKN45, was a significant factor in selecting the Lipofectamine reagent for use 
in all future transfections (Table S3.1.1 for data). 
  
To find the optimal level of EBNA1 expression, different quantities (0, 2 or 4µg/ml) of pCDNA3-
E1ΔGA were used for the transient transfection of the epithelial cell lines (MKN1, MKN28, 
MKN45, 293FT, HeLa and HaCaT). The transfected cells were harvested after 72h and EBNA1 
levels were assessed using western blotting (Figure 3.1.6). For all cell lines except HaCaT, the 
transfection using 4µg/ml DNA resulted in good levels of EBNA1 expression, surpassing 
physiological levels of EBNA1 seen in the LCL or MKN28 cell lines. Surprisingly low levels of 
EBNA1 were expressed in HaCaT cells, considering the levels of transfection efficiency that had 




apart from HaCaT, the EBNA1 expression levels roughly correlated with the previously 
determined transfection efficiencies; high levels for MKN28 and 293FT cell lines compared to 
lower levels in MKN1, MKN45 and Hela cell lines.  
  
An EBNA1 stability assay was attempted to measure the natural degradation of EBNA1 over 
time. However, assessing the results of the stability assay was hindered by the technical 
limitation of low protein yields harvested from transfected cells treated with cycloheximide. After 
upscaling the experiment, data was generated for MKN1, MKN28, HeLa and MJS cell lines. The 
cell lines were transfected with pCDNA3-E1ΔGA (4µg/ml), allowing 48h for EBNA1 levels to 
accumulate. Protein synthesis was then inhibited by the addition of cycloheximide (50µg/ml) and 
cells were chased for 0, 4, 8 or 24h. The protein levels were standardised and the levels of 
EBNA1 assessed using western blotting (Figure 3.1.7). In all cell lines, the consistent band 
intensity shown across 24h, in comparison to the BIP loading control, demonstrated high levels 
of EBNA1 stability within the epithelial cells. In contrast, the short lived protein cyclin D2 shows 
rapid degradation, with a half-life of <4h after treatment with cycloheximide. 
  
Following on from these results, it was important to assess whether the epithelial cell lines 
possessed functional autophagy pathways. As the Tellam et al. study demonstrated that the 
rapid degradation of EBNA1 was unaffected by proteasome inhibition [47], this suggested an 
alternative mechanism for the low levels of stability observed. Autophagy could be a mechanism 
for this, as it is an important pathway for EBNA1 processing and presentation in B cells [25]. 
Therefore, the high levels of EBNA1 stability observed in the epithelial cell lines I was testing 
might be explained if the same cell lines were found to lack functional autophagy pathways. The 
levels of autophagy were measured using the gold standard method of a LC3 flux [56], which 




inhibitor (bafilomycin A1). The LC3 flux was performed in cell lines (MKN1, MKN28, Hela, 
HaCaT and MJS) under normal culturing conditions (10% FCS) and serum starvation (0% FCS), 
which is known to increase autophagy, for 6h. The LC3-II levels were assessed using western 
blotting (Figure 3.1.8). This analysis demonstrated that the HeLa, MKN1 and MKN28 cell lines 
have high levels of basal autophagy, which can be upregulated by serum starvation. The results 
also showed that the LC3-II level in the HaCaT cell line was low, but autophagy is active both 
basally and under serum starvation. The exception here was the MJS cell line, which showed no 
basal autophagy; autophagy could however be upregulated upon serum starvation. By relating 
these results to the previous experiment, it was apparent that a lack of basal autophagy was not 
responsible for the EBNA1 stability within these epithelial cell lines. 
  
As the nuclear location of EBNA1 protects it from autophagic degradation [45], in theory a 
cytoplasmic-EBNA1 variant may not be granted the same protection and might therefore have 
lower levels of endogenous stability in cells that have high autophagy levels. To assess if the 
high basal levels of autophagy within the epithelial cells would affect the endogenous stability of 
cytoplasmic-EBNA1, cell lines (HeLa and MKN28) were transfected with pCDNA3-E1ΔNLk/o 
(4µg/ml) and cultured for 48h to allow EBNA1 levels to build up. Protein synthesis was then 
inhibited with the addition of cycloheximide (50µg/ml) and cells were chased for 0,4,8 or 24h. 
The levels of EBNA1 were determined using western blotting (Figure 3.1.9). Despite the high 
levels of autophagy within both cell lines, levels of cytoplasmic-EBNA1 (in comparison to the bip 
loading control) did not decrease over 24h. Unfortunately, two short life protein controls cyclin 
D2 and cyclin E were completely undetectable in cells treated with cycloheximide, although both 







Figure 3.1.5 Comparison of transfection reagents for use on epithelial cell lines   
The reagents Lipofectamine 2000 or Mirus Transit X2 were used to transfect the cell lines 
(MKN1, MKN28, MKN45, NUGC4, HeLa, 293FT and HaCaT) with 4µg/ml pCDNA3-GFP. Flow 
cytometry was used to assess transfection efficiency (GFP expression) and cell viability 
(propidium iodide staining), using mock transfected cells as a baseline reference point (Table 
S3.1 for values). Intact cells were analysed by gating on this population using forward scatter 
and side scatter (not shown). The results demonstrate that the cell viability was generally high 
(between 80-100%) for both reagents, but Lipofectamine transfections were consistently better, 
or as good as Muris transfection. The efficiency of transfections varied between the two reagents 
depending on the cell line; significantly however, a three-fold increase was seen for two gastric 








Figure 3.1.6 Optimisation of DNA concentration for the transfection of epithelial cell lines  
Western blot analysis of EBNA1 protein levels in cells (MKN1, MKN28, MKN45, 293FT, HeLa 
and HaCaT). The cells were transfected with pCDNA3-E1ΔGA (0, 2 or 4ng/ml) and cultured for 
48h before harvesting. Protein levels were standardised and EBNA1 levels were assessed by 
western blotting. Supraphysiological levels of E1ΔGA expression were seen from 4ng/ml 
transfections in all cell lines except HaCaT. An LCL was used as a positive control to indicate 
physiological levels of EBNA1 and mock transfected cells (0µg/ml) served as negative control for 
each cell line (illustrating the specificity of the antibody 1H-4). Note that MKN1, MKN28, MKN45 
and LCL samples were run and developed on the same blot. A second blot was used to run and 












Figure 3.1.7 Analysis of E1ΔGA stability in transfected MJS and epithelial cell lines    
A and B) The epithelial cell lines (HeLa, MKN1 and MKN28) and MJS were transfected with 
pCDNA3-E1ΔGA (4ng/ml) and cultured for 48h. Protein synthesis was then inhibited with the 
addition of cycloheximide (50µg/ml) and cells were chased for 0, 4, 8 or 24h. Samples were 
standardised and EBNA1 levels were assessed using western blotting. The consistent band 
intensity shown across 24h demonstrates that EBNA1 levels were stable in comparison to the 
loading controls for all cell lines. The blot was probed for Cyclin D2, serving as a positive control 
for a short lived protein, as seen by the rapid decrease in band intensity after 4h for all cell lines. 
A) Protein loading was assessed by probing the blot for BIP. B) Protein loading was assessed 
using ChemiDoc analysis of gel.  Note that HeLa and MJS and LCL samples were run and 








Figure 3.1.8 Analysis of autophagy (LC3) flux in MJS and epithelial cell lines 
Epithelial cell lines (HeLa, HaCaT, MKN1 and MKN28) and MJS were cultured for 6h under 
normal culturing conditions (serum +) and under starvation (serum -), either with treatment of 
bafilomycin A1 (100nM), an inhibitor of lysosomal acidification, or untreated. The cells were 
harvested and standardised before determining LC3-II levels using western blotting. With the 
exception of MJS, all cell lines showed an increase in LC3-II band intensity with treatment of 
bafilomycin A1, indicating active levels of autophagy. This effect was increased further upon 
serum starvation. Whilst the LC3-II levels in HaCaT are low, autophagy is active both basally 
and under serum starvation. For MJS cells the LC3-II band intensity only increased from the 
addition of bafilomycin A1 when cells were serum starved.  Note that samples from HaCaT 
(serum +) and all samples from HeLa and MJS were run and developed on the same blot. A 










Figure 3.1.9 Analysis of E1ΔNLSk/o stability in transfected epithelial cell lines 
Cell lines (HeLa and MKN28) were transfected with pCDNA3-E1ΔNLk/o (4ng/ml) and cultured 
for 48h. Protein synthesis was then inhibited with the addition of cycloheximide (50µg/ml) and 
EBNA1 was chased for 0, 4, 8 or 24h. The samples were standardised and EBNA1 levels were 
assessed using western blotting. The consistent band intensity, in comparison to the BIP loading 
control, shown across 24h demonstrates that E1ΔNLk/o is stable over 24h despite its 
cytoplasmic location. The blot was stripped and re-probed for short lived protein controls, cyclin 
D2 and cyclin E, but neither could be visualised for all the cells treated with cycloheximide. Note 







 3.2 EBNA1 Presentation to CD4 T cells 
  
3.2.1 EBNA1 specific CD4 T cell recognition of transfected epithelial cells  
The previous results demonstrated that supraphysiological levels of both nuclear and 
cytoplasmic-EBNA1 were stable in epithelial cell lines, even in those possessing high levels of 
basal autophagy. Previous studies have illustrated that despite the stability of EBNA1 in B cells, 
there is still effective CD4 T cell recognition of MHC class II epitopes. The principle of effective 
CD4 T cell recognition relying on small quantities of processed protein may also apply to 
epithelial cells, where only small amounts of EBNA1 are degraded. I therefore conducted 
experiments to assess the ability of CD4 T cells to recognise epithelial cells’ presentation of 
different EBNA1 variants, each with different abilities to access the MHC class II processing 
pathway. 
 
Before conducting CD4 T cell assays, the epithelial cell lines were assessed to determine if they 
were capable of presenting MHC class II. The cell lines (MKN1, MKN28, MKN45, HeLa, HaCaT 
and 293FT) were cultured with and without IFNγ (100ng/ml) for 72h and then stained with 
conjugated antibodies specific for MHC class I or II. Levels of MHC presentation were 
determined using flow cytometry (Figure 3.2.1). The results demonstrated that without IFNγ, 
none of the epithelial cell lines presented MHC class II. However, with the exception of 293FT, 
all of the cell lines had MHC class II presentation induced by the addition of IFNγ. Furthermore, 
whilst most cell lines naturally expressed MHC class I in the absence of IFNγ, the MKN45 cell 
line did not express MHC class I even with the addition of IFNγ. The experiment was repeated 
for MKN45 and 293FT cell lines and these results were confirmed. The fact that some EBV-




II, in the presence of cytokines, highlights the potential value of CD4 T cell responses against 
EBNA1. 
 
Previous work in the laboratory by Leung and colleagues had extensively characterised the 
ability of two EBNA1 specific CD4 T cells clones, SNP (DR51-restricted) and VYG (DR11-
restricted), to recognise LCLs [45]. I utilised these T cells for my novel investigation into 
epithelial cells presenting EBNA1 epitopes. A series of preliminary T cell assays were performed 
to determine whether the epithelial cell lines were HLA-matched for these, or potentially other, T 
cell clones available in the laboratory. The cell lines (Hela, HaCaT, 293FT, MKN1, MKN28 and 
MKN45) were incubated with IFNγ for 72h, allowing for the upregulation of MHC class II. The 
cells were then peptide pulsed with each T cell clone’s cognate peptide. A T cell assay was then 
performed and the level of IFNγ released by the T cells was measured using an ELISA (Table 
3.2.1). The only positive match to an EBNA1 T cell clone was MKN45 (DR51) (Table S3.2.1). 
Unfortunately, due to technical difficulties, the HaCaT and MKN45 cell lines could no longer be 
cultured, resulting in these cell lines, along with 293FT cells (which could not present MHC class 
II), not being used in the future CD4 T cell assays. Therefore, to assess CD4 T cell recognition 
of EBNA1 epitopes, all  epithelial cell lines required a co-transfection with plasmid encoding 
EBNA1 and the appropriate HLA type (as well as treatment with IFNγ to induce expression of 
MHC class II) prior to each T cell assay. It is worth noting here that an MJS cell line, which was 
not present in this experiment but used in the following T cell assays, is different to the sub-line 
used in the previous experiments on EBNA1 stability. Importantly, this new MJS cell line was not 
matched to either HLA DR11 or DR51 and, conversely to the previous MJS line, possessed 





To determine the optimal levels of DNA to be co-transfected into cell lines for the most effective 
T cell recognition, various amounts of DNA (0.2, 0.6 or 2µg/ml) for both HLA (DR51) and EBNA1 
(E1ΔNLSk/o) were used in a co-transfection of MJS and MKN28 cell lines (Figure 3.2.2). The 
results demonstrate that the optimal levels of DNA were 2ng/ml for EBNA1 and 0.6µg/ml of HLA-
type. Samples from this experiment were also run on a western blot probing for EBNA1. This 
allowed a comparison between the amount of DNA transfected into the cells and physiological 
levels.  
  
As well as testing the abilities of different EBNA1 variants to access the MHC class II processing 
pathway, the CD4 T cell assays were also used to compare two different epitopes, one of which 
was autophagy independent (VYG) and the other autophagy dependent (SNP) in B cells. The 
epithelial cell lines (MKN1, MKN28, MJS, HeLa and HaCaT) were co-transfected using one of 
several EBNA1 constructs (E1ΔGA, E1ΔNLSk/o or IiE1Δ) and a plasmid encoding HLA class II 
(DR11 or DR51) and treated with IFNγ for 72h. The transfected cells were then used in a T cell 
assay with CD4 T cells (VYG or SNP). The IFNγ release from this assay was measured using an 
ELISA. With a few exceptions, the same pattern of VYG T cell recognition for the different 
EBNA1 constructs was seen across all epithelial cell lines (Figure 3.2.3). The model cell lines 
HeLa and MJS followed the expected pattern of EBNA1 variant recognition; low levels for 
nuclear EBNA1 with increased levels for cytoplasmic and the highest for the one tagged with 
invariant chain. This was followed by the maximum response for the cells pulsed with cognate 
peptide. Surprisingly, both gastric carcinoma cell lines, MKN1 and MKN45, deviated from this 
pattern with respect to the cytoplasmic-EBNA1, which showed lower recognition than the nuclear 
variant. For SNP, the same pattern of T cell recognition of different EBNA1 constructs was 
consistent across all epithelial lines (Figure 3.2.4). As expected, recognition of EBNA1 variants 




tagged with an invariant chain. However, transfected cells pulsed with the cognate peptide for 
SNP showed lower levels of recognition than IiE1Δ.The mechanism for this consistent pattern of 
results across multiple experiments was unclear, as peptide pulsing was clearly functional as 
shown by the results from the HLA matched LCL control response. It was also notable that the 
MJS cell line had much higher levels of SNP T cell recognition for cytoplasmic-EBNA1, including 
the ratio of this to IiE1Δ, in comparison to other epithelial cell lines 
  
All epithelial cell lines were capable of presenting autophagy dependent and independent 
epitopes to CD4 T cells. With a few exceptions, the hierarchy of EBNA1 variants’ access to the 
processing pathway, previously shown in LCLs, appears to also apply to epithelial cells. 
However, it is difficult to compare levels of presentation between the epithelial cell lines or even 









Figure 3.2.1 Analysis of MHC class I and II presentation for epithelial cell lines (+/- IFNγ)  
Flow cytometry analysis of MHC class I and II surface presentation for epithelial cell lines 
(MKN1, MKN28, MKN45, HeLa, HaCaT and 293FT), cultured for 72h with or without the 
treatment of IFNγ (100ng/ml). The cells were then stained using conjugated antibodies APC-
antihuman HLA-A,B,C and HLA-DR for the detection of MHC class I and II respectively (FL4 
channel). Intact cells were analysed by gating on this population using forward scatter and side 
scatter (not shown). The MHC surface presentation was compared between unstained cells 
(black line), stained cells of the same line that had not been treated with IFNγ (red line) and 
stained cells that had been treated with IFNγ (100nm/ml)(blue line). An LCL possessing high 
levels of MHC class I and II was used as a positive control. The analysis demonstrated that 
without IFNγ, none of the epithelial cell lines present MHC class II. However, for all cell lines, 
with the exception of 293FT, the addition of IFNγ was sufficient to induce MHC class II 
presentation. The results also demonstrated that MKN45 had completely lost MHC class I 












Table 3.2.1 Analysis of epithelial cell lines HLA restriction by T cell assay   
The cell lines (Hela, HaCaT, 293FT, MKN1, MKN28 and MKN45) were incubated with IFNγ for 
72h to induce the expression of MHC class II. The cells were then peptide pulsed with each T 
cell clone’s cognate peptide. A T cell assay was then performed and IFNγ release was 














Figure 3.2.2 Optimisation of co-transfection for T cell assays for epithelial cell lines 
A) ELISA analysis of IFNγ release assay from CD4 T cell, SNP, recognition of cell lines (MJS 
and HeLa) co-transfected with various concentrations of DNA plasmid (2, 0.6 or 0.2µg/ml) for the 
nine possible combinations of HLA (DR51) and EBNA1 (E1ΔNLSk/o). For all transfections, 
EBNA1 concentration was the limiting factor and the mid-level HLA concentration provided the 
optimal condition for T cell recognition. A HLA matched LCL was pulsed with the cognate 
peptide as a positive control, demonstrating T cell viability. B) Western blot analysis of 
E1ΔNLSk/o in MKN28 cells transfected with various concentrations of E1ΔNLSk/o. This blot 
demonstrated that the expression levels of transfected levels of DNA (even for the lowest 
concentration) were much higher than physiological levels of the full length EBNA1 naturally 





Figure 3.2.3 Analysis of VYG CD4 T cell assay with epithelial cell lines transfected with 
various EBNA1 constructs 
ELISA analysis of IFNγ released from a T cell assay using a CD4 T cell clone (VYG) against 
target cell lines (MJS, HeLa, MKN1 and MKN28) co-transfected with a plasmid encoding HLA 
DR11 (0.6µg/ml) and a pCDNA3-EBNA1 plasmid (2µg/ml E1ΔGA, E1ΔNLSk/o or IiE1Δ) or an 
empty vector (pCDNA). The negative control, pCDNA (p-), was used as a benchmark (0pg/ml 
IFNγ). Physiological levels of T cell recognition against the endogenous EBNA1 protein present 
in MKN28 have therefore been subtracted to facilitate direct comparison of the various EBNA1 
constructs. For the positive control, pCDNA (p+), some of the cells transfected with pCDNA3 
were pulsed with synthetic VYG peptide to stimulate the maximum possible T cell response. 
With a few exceptions, the same pattern of VYG T cell recognition of EBNA1 constructs was 
observed across all epithelial lines over multiple experiments. The model cell lines, HeLa and 
MJS, followed the expected pattern of EBNA1 variant recognition; low levels for nuclear EBNA1, 
increased levels for cytoplasmic and highest for invariant chain. This was followed by the 
maximum response from the peptide pulsed cells. Surprisingly, both gastric carcinoma cell lines, 
MKN1 and MKN45, deviated from this pattern with respect to the cytoplasmic-EBNA1, which 
showed lower recognition than the nuclear variant. A HLA matched LCL was used as a positive 
control for the efficacy of the T cell, showing recognition of physiological levels of EBNA1 (p-) 






Figure 3.2.4 Analysis of SNP CD4 T cell assay with epithelial cell lines transfected with 
various EBNA1 constructs  
ELISA analysis of IFNγ release T cell assay, using a CD4 T cell clone (SNP) against target cell 
lines (MJS, HeLa and MKN28) co-transfected with a plasmid encoding HLA DR51 (0.6µg/ml) 
and a pCDNA3-EBNA1 plasmid (2µg/ml E1ΔGA, E1ΔNLSk/o or IiE1Δ) or an empty vector 
(pCDNA). The negative control, pCDNA (p-), was used as a benchmark at (0pg/ml IFNγ). 
Physiological levels of T cell recognition against the endogenous EBNA1 protein present in 
MKN28 have therefore been subtracted to facilitate the direct comparison of the various EBNA1 
constructs.  For the positive control, pCDNA (p+), some of the cells transfected with pCDNA3 
were pulsed with synthetic VYG peptide to stimulate maximum T cell response in the cell line.  
Recognition of EBNA1 variants followed the expected pattern; low levels of recognition for 
nuclear, increased levels for cytoplasmic and highest for invariant chain. Unexpectedly however, 
transfected cells pulsed with the cognate peptide for SNP then showed lower levels of 
recognition than IiE1Δ.The mechanism for this occurrence was unclear, as peptide pulsing was 
shown to be functional from the results of the HLA matched LCL (p+). It was also notable that 
the MJS cell line had much higher levels of SNP T cell recognition for cytoplasmic-EBNA1, 
including the ratio of this to IiE1Δ, in comparison to other epithelial cell lines. A HLA matched 
(DR51) LCL was used as a positive control for the efficacy of the T cell, showing recognition of 




3.2.2 Effect of EBV-encoded miRNA on autophagy and CD4 T cell recognition  
I next investigated the possible roles of miRNA in the processing and presentation of EBNA1. 
Data obtained by another laboratory suggested that the EBV-encoded miRNA BART 18 
suppresses autophagy (E. Wiertz, University of Leiden, personal communication). If this is the 
case, then the expression of BART 18 may in turn affect the processing and presentation of 
certain autophagy dependent epitopes of EBNA1. In order to test this hypothesis, I received two 
cell lines from Wiertz’s laboratory; an EBV-negative melanoma cell line (MJS) where miRNA was 
overexpressed and another EBV-positive Burkitt lymphoma B cell line (Jijoye) where miRNA was 
subject to knockout (k/o). The unmanipulated Jijoye cell line had previously been shown to 
express the BART 18 miRNA using m-R sensors. The Jijoye cell lines I received had been 
created using lentiviral transduction and positive selection to generate three sub-lines 
expressing different k/o miRNA plasmids: Empty vector (EV) k/o as a negative control, BART 16 
(B16) k/o as an extra negative control (although it could theoretically be possible for this miRNA 
to have an unknown role that could affect either autophagy or antigen presentation) and BART 
18 (B18) k/o. To test the effect of isolated B18 overexpression on autophagy levels and epitope 
presentation to CD4 T cells, an MJS cell line was selected as it possesses naturally high levels 
of MHC class II presentation and has previously been used as a model cell line for the study of 
antigen processing and presentation. The MJS cell lines I received had undergone lentiviral 
transduction and positive selection to generate four sub-lines overexpressing miRNA plasmids: 
EV overexpression, B16 overexpression, B18 overexpression and Cluster 1 (C1) overexpression 
(which contained BART 18-21). By experimenting with these two systems, loss of function and 






The autophagy levels in the MJS sub-lines overexpressing various miRNA vectors (EV, B16, 
B18 or C1) were assessed by performing an LC3 flux (previously described) (Figure 3.2.5). The 
data showed that all sub-lines had basal levels of autophagy under normal conditions, which 
were upregulated upon serum starvation. In terms of differences in autophagy levels between 
the miRNA constructs, the EV overexpression sub-line (negative control) showed much lower 
levels than the B16 overexpression (second negative control) sub-line. However, both these 
negative controls demonstrated lower levels of autophagy than the C1 and B18 overexpression 
sub-lines. This result appears to contradict the original hypothesis, as the individual expression 
of BART 18 caused an upregulation of autophagy levels rather than suppressing it.  
  
The autophagy levels in the Jijoye sub-lines expressing various miRNA k/o vectors (EV, B16 or 
B18) were assessed by performing an LC3 flux (previously described), after which the levels of 
LC3-II were determined using western blotting (Figure 3.2.6). Analysis showed that all cell lines 
had basal levels of autophagy under normal conditions, which was slightly increased upon 
serum starvation.  Under normal conditions, the LC3-II band intensity increase was stronger in 
the EV k/o and B18 k/o sub-lines than in the B16 k/o sub line. Under starvation however, band 
intensity increase was strongest in the B18 k/o sub-line, with lower levels in EV and lower levels 
still in the B16 k/o sub-line. This result suggested that BART 18 only acted to downregulate 
autophagy in times of physiological stress, such as starvation (Table S3.2.2). 
  
The effect of BART 18 on antigen presentation was then assessed in the various MJS and Jijoye 
sub-lines. Before performing T cell assays, it was important to measure the levels of MHC class 
II surface expression, as this might have impacted the levels of T cell recognition independently 
of the EBNA1 processing manipulated by miRNAs. All MJS and Jijoye sub-lines were cultured 




MHC class I or II then allowed assessment of MHC expression levels using flow cytometry 
(Figure 3.2.7). The results here demonstrate that there was no variation for MHC class II 
presentation levels between the different sub-lines for either the MJS or the Jijoye cell line. 
Interestingly, there was a subtle variation in the MHC class I presentation between different sub-
lines for both MJS and Jijoye cell lines. However, as I was not testing for CD8 T cell recognition 
this was not investigated further. The addition of IFNγ (10ng/ml) resulted in the upregulation of 
MHC class I and II equally for all MJS sub-lines, but had no impact on the Jijoye sub-lines; 
raising the concentration of IFNγ (100ng/ml) had no effect on these results (Figure S3.2.1). 
  
I then investigated whether the processing of the different EBNA1 constructs, each with a 
capability of accessing the MHC class II processing pathway, was affected by the 
overexpression of BART 18. The MJS sub-lines overexpressing various miRNA vectors (EV, 
B16, B18 or C1) were co-transfected using an EBNA1 construct (E1ΔGA, E1ΔNLSk/o or IiE1Δ) 
and a plasmid encoding HLA class II (DR51) and cultured with IFNγ (10ng/ml) for 72h. The 
transfected cells were then used in an SNP CD4 T cell assay and IFNγ release was measured 
using an ELISA (Figure 3.2.8). Equivalent levels of IFNγ production were seen in response in all 
sub-line variants, with a few exceptions. The C1 overexpression sub-line exhibited lower levels 
of recognition for E1ΔGA, IiE1Δ and peptide pulsed (P+). In the B18 overexpression sub-line the 
response to peptide pulsing was substantially higher than the other sub-lines. Finally, the C1 and 
EV overexpression sub-lines had lower responses for the nuclear EBNA1 in comparison to B18 
and B16 overexpression sub-lines. There was therefore no discernible pattern for the 
overexpression of BART 18 alone effecting EBNA1 presentation. 
  
To assess the effects of BART 18 loss of function on CD4 T cell recognition, the Jijoye sub-lines 




dependent epitope (SNP) against an autophagy independent epitope (VYG). As the EBV-
positive Jijoye cell line was naturally MHC class II positive and HLA matched to both T cells 
(restricted though DR11 and DR51), it was used directly in a T cell assay and IFNγ release was 
measured using an ELISA (Figure 3.2.9).  The B18 k/o sub-line showed a 0.5 fold increase in 
SNP T cell recognition compared to the two negative controls. For YVG T cell recognition the 
B18 k/o sub-line only showed a 0.2 fold increase from the two negative controls. Each cell line 
was pulsed with the cognate peptide of the T cell (SNP or VYG) as a positive control for 
maximum response. The SNP peptide pulsed cells showed consistent and strong recognition. 
However, a much weaker response was seen in VYG peptide pulsed cells, with a significantly 









Figure 3.2.5 Analysis of autophagy (LC3) flux within various MJS sub-lines 
overexpressing miRNA vectors 
Western blot  analysis of LC3-II levels in various MJS sub-lines overexpressing miRNAs (Empty 
vector, Cluster 1, BART 16 and BART 18) cultured for 6h under normal culturing conditions 
(serum +) and under starvation (serum -), either with treatment of bafilomycin A1 (100nM), an 
inhibitor of lysosomal acidification, or untreated. The cells were harvested and standardised 
before determining LC3-II levels using western blotting. All sub-lines showed an increase in LC3-
II band intensity upon inhibition of autophagy, indicating basal levels of autophagy. Band 
intensity increases were shown to be stronger for the C1 and B18 overexpression sub-lines 











Figure 3.2.6 Analysis of autophagy (LC3) flux within various Jijoye sub-lines expressing 
miRNA k/o vectors  
Western blot analysis of LC3 levels in various Jijoye sub-lines expressing miRNA k/o (Empty 
vector k/o, BART 16 k/o and BART 18 k/o) cultured for 6h under normal culturing conditions 
(serum +) and under starvation (serum -), either with treatment of bafilomycin A1 (100nM), an 
inhibitor of lysosomal acidification, or untreated. The cells were harvested and standardised 
before determining LC3-II levels using western blotting. All cell lines show basal levels of 
autophagy, with an increase in LC3 II band intensity upon autophagy inhibition. Under normal 
conditions, band intensity increases are seen to be stronger in the EV and B18 k/o sub-lines 
compared to the B16 k/o sub-line. Under starvation however, band intensity increase is 
strongest in the B18 k/o sub-line, with lower levels in the EV sub-line and lower levels still in the 






Figure 3.2.7 Analysis of MHC class I and II presentation of various Jijoye and MJS cell 
lines expressing miRNA constructs (+/- IFNγ) 
Flow cytometry analysis of MHC class I and II surface presentation was assessed in all Jijoye 
and MJS sub-lines expressing the various miRNA vectors (overexpression and k/o). The cell 
sub-lines were left untreated (left column) or treated with IFNγ (10ng/ml)(right column) for 72h. 
The cells were then stained using MHC class I and II conjugated antibodies HLA-DR and HLA-
A,B,C specific towards MHC class II and I respectively. Flow cytometry was used to measure 
fluorescence levels (FL2). Intact cells were analysed by gating on this population using forward 
scatter and side scatter (not shown). The MHC surface presentation was compared between 
unstained cells (black line) and stained cells (all other colours). Results show that both MJS and 
Jijoye cells are naturally MHC class I and II positive and the addition of IFNγ only causes 
upregulation in MJS cells. This result demonstrated that there was no difference in MHC class II 
surface presentation between the various miRNA sub-lines for either Jijoye or MJS. There was 
however a subtle variation in the MHC class I presentation between different sub-lines for both 






Figure 3.2.8 Analysis of SNP CD4 T cell assay with various MJS sub-lines, overexpressing 
different miRNA vectors, transfected with various EBNA1 constructs 
ELISA analysis of IFNγ release from a T cell assay, using SNP T cell clones against target MJS 
sub-lines overexpressing miRNA (Empty vector, Cluster 1, BART 16 and BAR 18), co-
transfected with plasmid encoding HLA-DR51 (0.6µg/ml) and an EBNA1 construct (2µg/ml), 
E1ΔGA, E1ΔNLSk/o or IiE1Δ, or pCDNA (2µg/ml). The results demonstrated similar levels of 
recognition between MJS sub-lines for each construct, with a few exceptions. The C1 
overexpression sub-line exhibited lower levels of recognition for E1ΔGA, IiE1Δ and peptide 
pulsed (P+). In the B18 overexpression sub-line the response to peptide pulsing was 
substantially higher than in the other sub-lines. Finally, the C1 and EV overexpression sub-lines 












Figure 3.2.9 Analysis of SNP and VYG CD4 T cell assays with various Jijoye sub-lines 
expressing different miRNA k/o vectors  
CD4 T cells, SNP or VYG, were incubated with the various Jijoye sub-lines expressing miRNA 
k/o vectors (Empty vector, BART 16 and BART 18), which had been peptide pulsed (P+) or left 
untreated (p-). The IFNγ release from the T cell assay was measured using an ELISA. For SNP 
recognition, the untreated B18 k/o sub-line showed a 0.5 fold increase in IFNγ levels compared 
to the two native controls, whilst the peptide pulsed cells for all sub-lines showed consistent 
recognition. Results from VYG demonstrated fairly even recognition across all miRNA variants. 
However, a very weak response was seen from the VYG peptide pulsed cells, especially from 








3.3 EBNA1 inhibition 
Previous research has demonstrated that the inhibition of EBNA1 using dominant-negative 
inhibitors leads to an increase in MHC class I and MHC class II presentation of EBNA1 epitopes, 
which results in more effective T cell recognition [52]. Augmenting infected cells to improve T cell 
recognition may have applications in the immunotherapy of EBV-associated diseases. Until now, 
an investigation into whether pharmacological inhibitors of EBNA1 dimerisation have this same 
impact on T cell recognition has not been conducted.  
 
3.3.1 Pharmacological inhibition of EBNA1 dimerisation for the manipulation of CD4 T cell 
recognition 
Recently, an EBNA1 dimerisation inhibitor, JLP2, was designed using molecular computation 
[55]. The presence of the JL chromophore allowed the molecule to be visualised with confocal 
microscopy and quantified with flow cytometry. Upon treatment with JLP2, an EBV-positive NPC 
cell line was selectively visualised and was found to have reduced viability compared to the 
EBV-negative HeLa line. The collaborating laboratory (G. Wong, Hong Kong Baptist University) 
provided me with both JLP1 and JLP2 peptides. By treating EBV-positive cell lines with JLP2, I 
explored the specific visualisation, the effects on cell viability and the effects on CD4 T cell 
recognition. 
  
Firstly, the fluorescent inhibitors were tested to see if they could effectively be used for the 
visualisation of EBV-associated cancer cell lines. EBV-positive cell lines (SNU, MKN28 and LCL 
(GT)) expressing EBNA1 and EBV-negative cell lines (MKN1 and HeLa) were both treated with 
JLP1 or JLP2 (20µM) for 12h. The fluorescence intensity was then assessed using fluorescent 
microscopy (Figure 3.3.1). For both JLP1 and JLP2 there appeared to be non-specific 




Upon testing the peptide alone (i.e. with no cells present), there was artifactual fluorescence 
from JLP2, with intensity levels that appeared almost as strong as when on cells. JLP1 was not 
used in any of the future experiments, as I wished to further investigate the claims regarding the 
JLP2 emission spectrum shift upon binding to EBNA1 and its effect on cell viability.   
  
To more accurately assess JLP2 binding to EBNA1, flow cytometry was used to quantify the 
levels of green fluorescence. EBV-positive B cells, LCLs (GT and GS), were compared to EBV-
negative B cells (Akata and Awaia), both having been treated with JLP2 (0 and 20µM) for 72 
hours. Fluorescence was then assessed using flow cytometry (FL1) (Figure 3.3.2). The results 
demonstrated that there was no fluorescence intensity change for either of the EBV-negative B 
cell lines treated with JLP2. However, there was a small rise in FL1(H) median intensity for both 
EBV-positive LCLs treated with JLP2, more prominently seen in LCL (GT). The small, but 
observable increase in fluorescence intensity suggested that specific binding of JLP2 was only 
occurring in EBV-positive B cell lines. However, a lower dose of JLP2 (5µM) was not sufficient to 
induce the increase in fluorescence for either EBV-positive LCL (data not shown). 
  
Next, I was interested in replicating the previously published results showing JLP2’s selective 
effect on reducing the viability of EBV-positive cell lines; in this previous model a comparison 
was made between C666.1 (EBV-positive NPC) and HeLa (EBV-negative epithelial) cell lines 
[55]. As these cell lines were from two completely different backgrounds, they were likely to 
behave differently in many ways. Therefore, for my experiment I decided to compare EBV-
positive and negative cells from a similar B cell background. To assess JLP2’s effect on cell 
viability, a WST-1 assay was optimised to find the best duration and density of B cells (Figure 
3.3.3). The effect of JLP2 on B cell proliferation was measured in various cell lines, which were 




were treated with various concentrations of JLP2 (0, 1, 5, 10 or 20µM) and chased for 4, 24, 48 
or 72h. A 1h WST-1 assay with 5x104 cells was used to measure cell viability (Figure 3.3.4). 
The results demonstrate that JLP2 had a dose dependent effect, lowering the cell viability for the 
EBV-positive LCL (GT) after 4 hours; this effect was however reduced after 24h and completely 
lost after 48h. The JLP2 treatment did not have this effect on the cell viability of the two EBV-
negative lines, but also did not affect the other EBV-positive LCL (GS). This suggested that in 
susceptible cell lines, the effect of JLP2 was very immediate but also transitory.  
  
Finally, CD4 T cell recognition of JLP2-treated cell lines was assessed. HLA matched LCLs, GT 
(DR51) and GS (DR11), were treated with various concentrations of JLP2 (0, 10 or 20µM) and 
used in a CD4 T cell assay with SNP (DR51) or VYG (DR11). The levels of IFNγ release were 
assessed using an ELISA (Figure 3.3.5). For both epitopes, a very slight increase was seen 
upon treatment with JLP2, however the effect was not dose dependent. Therefore it can be 
concluded that JLP2 did not appear to have a significant effect on the antigen processing for the 






   
 
Figure 3.3.1 Visualisation of EBNA1 inhibitors, JLP1 and JLP2, treatment for various EBV-
positive and negative cell lines 
Fluorescence microscopy was used to visualise EBV-positive cell lines (SNU, MKN28 and LCL 
(GT)) and EBV-negative cell lines (MKN1 and HeLa) treated with either JLP1 or JLP2 (20µM) for 
12h. The same field of cells was visualised under bright field and UV light to show the binding 
behaviour of JLP1 and JLP2. For both JLP1 and JLP2 there appeared to be non-specific binding 
for all cell lines regardless of EBV status. In the negative control, peptide alone with no cells 
(blank), there was no fluorescence of JLP1 but observable artifactual fluorescence of JLP2.  






                                                                          
Figure 3.3.2 Analysis of JLP2 fluorescence in various EBV-positive and negative B cell 
lines  
JLP2 fluorescence was assessed by flow cytometry in EBV-positive (LCL (GT) and LCL (GS)) 
and EBV-negative (Akata and Awaia) B cells, treated with JLP2 (0 or 20µM) for 72 hours. Intact 
cells were analysed by gating on this population using forward scatter and side scatter (not 
shown). The results showed a rise in FL1-H intensity for both EBV-positive LCLs treated with 
JLP2, more prominently seen in LCL (GT), which is not seen in the EBV-negative B cell lines. 






                 
 
Figure 3.3.3 Optimisation for duration and B cell density for WST-1 proliferation assay  
WST-1 proliferation assays were performed to find the optimal cell seeding density and time 
duration for use in future assays. WST-1 (10µl) was added to the LCL seeded at various 
densities (50, 25, 12.5, 6.3, 3.1, 1.6 or 0x103). The samples absorbance (450nm) was measured 
at various time points over 4h (0.5, 1, 2, 3 or 4). The 5x104 cell density incubated with WST-1 for 
1h was used in future assays as it was most suitable for measuring cell proliferation and 







Figure 3.3.4 Analysis of JLP2 treatment’s effect on the cell viability of various EBV-
positive and negative B cell lines 
EBV-positive (LCL (GT) and LCL (GS)) and EBV-negative (Akata and Awaia) B cells were 
treated with various concentrations of JLP2 (20, 10, 5, 1 or 0µM). The proportion of viable cells 
was determined at 4, 24, 48 or 72h after JLP2 treatment using a WST-1 assay. A JLP2 dose 
dependent effect on cell proliferation of LCL (GT) was observed after 4h, which reduced after 
24h and was lost after 48h. The JLP2 treatment did not appear to have this effect on the two 









Figure 3.3.5 Analysis of VYG and SNP CD4 T cell recognition of EBV-positive LCLs 
treated with various concentrations of JLP2  
HLA matched LCL targets for CD4 T cells SNP (DR51 - LCL (GT)) and VYG (DR11 - LCL (GS)) 
were treated with various concentrations of JLP2 (0,10 or 20µM) and used in a T cell assay. The 
IFNγ release was assessed using an ELISA. The results here demonstrated that for both 
epitopes a very slight increase was seen upon treatment with 10µM JLP2. This increase was 
sustained for VYG when the dose was increased to 20µM but not for SNP. Peptide pulsed (P+) 
LCLs were used as positive control and demonstrated the efficacy of the T cell clone. The IFNγ 






4. Discussion  
 
This work offers a novel perspective on EBNA1 processing and MHC class II presentation in the 
context of epithelial cancers. Over 200,000 malignancies each year are associated with EBV 
infections and the majority of these are found in epithelial cell backgrounds [42]. However, 
scientific research and clinical trials on the treatment of EBV-associated malignancies have 
almost exclusively focused on B cell lymphomas. The clinical relevance of utilising EBV targets 
for the treatment of EBV-associated diseases has been highlighted by the success of 
immunotherapies, such as adoptive T cell transfer for PTLD patients [33]. There is great 
potential to expand treatment options to cover the large number of patients with EBV-associated 
epithelial malignancies. Initial in vitro laboratory work studying relevant cell lines must be 
conducted first to elucidate the most appropriate effector T cell phenotype and EBV target for the 
treatment of these epithelial malignancies. In this study I investigated the CD4 T cell response to 
the EBV-encoded protein EBNA1 in the context of epithelial cells.   
 
Within inflammatory tumour microenvironments, the presence of cytokines (such as IFNγ) can 
induce MHC class II presentation in many epithelial cell types, allowing for CD4 T cell 
recognition [57]. Moreover, cancer cells can be effectively controlled and even directly killed by 
CD4 T cells [16, 35]. The latent protein EBNA1, expressed within all EBV-associated 
malignancies, has a much wider range of epitopes for MHC class II compared to MHC class I. 
Thus, there is great potential in exploring whether EBNA1-specific CD4 T cells are effective at 
targeting and controlling EBV-associated malignancies. A study by Tellam and colleagues 
demonstrated that EBNA1 has a short half-life in an epithelial background compared to the long 




was shown to be independent of proteasomal degradation, the mechanism for this degradation 
remains unclear and has not been explored further in the literature. One possibility is an 
autophagy dependent mechanism. If EBNA1 is susceptible to high levels of autophagic 
degradation in epithelial cells, more so than in B cells, this may contribute to more effective 
epitope presentation and greater levels of CD4 T cell recognition.  
 
This project aimed to study EBNA1 stability and presentation to CD4 T cells in the context of 
epithelial malignancies. Furthermore, the claim that EBV-encoded miRNA BART 18 suppresses 
autophagy, potentially as a CD4 T cell recognition evasion strategy, was assessed. Tangentially, 
CD4 T cell recognition was also used to explore the possibility of using a pharmacological 






4.1 Endogenous stability of EBNA1 
The results from Tellam et al. demonstrated that the endogenous stability of EBNA1 varied 
depending on cell type [47]. The expected long half-life (>30h) of EBNA1 expressed in B cells 
was shown, but a much shorter half-life was observed in the three epithelial lines tested. To 
expand on this work, I used several epithelial cell lines that were physiologically relevant to EBV-
associated malignancies in which to study the endogenous stability of EBNA1.   
 
4.1.1 The stability of EBNA1 in lentiviral transduced epithelial cell lines 
Five epithelial cell lines were successfully transduced by an infectious lentivirus containing 
genes for an inducible full length EBNA1, as shown by the proportion of cells expressing GFP 
measured by flow cytometry. However, the inducible-EBNA1 gene could only be induced to low 
levels of expression, which did not reach the equivalent physiological level of EBNA1. The 
doxycycline (used for inducing gene expression) was independently validated by a separate 
experiment, where it induced the expression of a dox-regulated gene (data not shown). Because 
of the low level of EBNA1 expression, data from an EBNA1 stability assay was only generated in 
MKN1 and MKN28 cell lines. This experiment demonstrated that there was no apparent 
degradation of EBNA1 over the 24h chase, indicating high levels of stability (similar to the 
previously published results in B cells). As the MKN28 cell was naturally EBV-positive, stronger 
bands were seen in the western blot analysis due to the combination of physiological and 
induced EBNA1 expression. Technical challenges meant that this experiment lacked a loading 
control but the results suggest that EBNA1 levels remained mostly unchanged in these cell lines. 
Rather than attempting to fix the lentiviral system, I decided to focus on the key biological 






4.1.2 The stability of EBNA1 in transiently transfected epithelial cell lines   
Optimisation experiments were performed to determine an appropriate transfection reagent and 
DNA concentration in order to generate supraphysiological expression of EBNA1 within the 
epithelial cell lines. Lipofectamine 2000 was selected as the transfection reagent, as it was three 
times more efficient in the transfection of two gastric carcinoma cell lines (MKN1 and MKN45) 
compared to the alternative transfection reagent Mirus Transit X2. The DNA concentration of 
4µg/ml was chosen, as this demonstrated consistent supraphysiological expression of EBNA1 
within all cell lines except HaCaT. Despite adequate transfection efficiency (35% shown by flow 
cytometry), only low levels of protein were seen for transfected HaCaT cells by western blot 
analysis. The HaCaT line was included in this study, as it was previously reported by Tellam et 
al. that EBNA1 had a very short half-life (<4h) in this cell background. However, I was only able 
to obtain a single preliminary result from the HaCaT cell lines (Figure S4.1.1), which suggested 
EBNA1 was stable with a long half-life in this cell background. Additional experiments in the 
HaCaT cell line would be needed to confirm this result. 
 
To test the endogenous stability of EBNA1, the epithelial cell lines were transfected with a 
plasmid encoding E1ΔGA and a stability assay was conducted. I chose to use an E1ΔGA 
plasmid as it expresses higher levels of protein and Tellam et al. reported that there was no 
difference in the stability of full length EBNA1 compared to E1ΔGA expressed in either B cells or 
epithelial cells. The results from this stability assay demonstrated that for all tested cell lines, 
supraphysiological levels of E1ΔGA were stable and consistent in relation to the loading control 
BIP across the 24h chase, while a short-lived control protein was rapidly degraded in less than 
4h. The data shown here is therefore inconsistent with the hypothesis of low EBNA1 stability 
levels in an epithelial cell background. However, as no mechanism explaining the short half-life 




this still left the possible explanation of autophagy dependent degradation. Potentially, if the 
epithelial cell lines that I was using had no, or low, levels of basal autophagy compared to the 
epithelial cells used by Tellam et al., this could explain the apparent stability of EBNA1 in my 
assays. However, upon measuring autophagy levels with an LC3 flux assay, all of the epithelial 
cell lines had high levels of basal autophagy under standard culturing conditions. The 
mechanism explaining the difference seen between my results and Tellam et al. was not 
discovered; potentially this could have been due to differences in the culturing, transduction or 
even variation between sub-lines of the same cell type. However, the principle of low stability of 
EBNA1 within epithelial cells is not supported by this data. 
 
A cytoplasmic version of EBNA1 may be subject to higher levels of degradation, as the nuclear 
location of EBNA1 protects it from autophagic degradation [33]. However, upon testing gastric 
carcinoma cell lines (MKN1 and MKN28) transduced to express supraphysiological levels of 
E1ΔNLSk/o, the levels of cytoplasmic-EBNA1 did not decrease in comparison to the BIP loading 
control during a 24h stability assay. Although probing for two short lived protein controls was 
unsuccessful in both epithelial cell lines, all reagents used here had previously been tested and 
shown to work. Even with high levels of stability, only small amounts of protein degradation are 








4.2 CD4 T cell recognition of EBNA1 epitopes  
 
4.2.1 EBNA1 specific CD4 T cell recognition of transfected epithelial cells   
Despite the fact that EBNA1 appears stable within B cells, there is still enough endogenous 
processing to facilitate effective MHC class II presentation of EBNA1 epitopes to CD4 T cells. 
Although my previous work demonstrated that EBNA1 is stable within the epithelial cell lines, 
this does not discount the possibility of small levels of degradation providing enough MHC class 
II presentation for effective recognition by CD4 T cells. A study exploring the viral effects on 
antigen presentation in the melanoma cell line MJS (transfected with plasmids encoding for 
E1ΔNLSk/o and HLA-DR51) demonstrated that the expression of cytoplasmic-EBNA1 allowed 
for high levels of CD4 T cell recognition of the autophagy dependent epitope SNP [58]. To 
expand on this work, I designed systematic analyses measuring the recognition of different 
EBNA1 variants (each with different abilities to access the MHC class II processing pathway) in 
the context of epithelial cell lines and the MJS cell lines. Except for the 293FT cell line, all 
epithelial cell lines upregulated cell surface MHC class II levels in the presence of IFNγ. Whilst 
some of these expression levels were lower than the levels seen in B cells, they were high 
enough to elicit CD4 T cell recognition. By running a preliminary T cell assay, I discovered that 
none of the epithelial cell lines (that would go on to be used in future T cell assays) were HLA 
matched to the two EBNA1 CD4 T cell clones used (SNP-DR51 and VYG-DR11) in our 
laboratory. Therefore, all of the cell lines required co-transfection with an EBNA1 construct and a 
plasmid encoding an appropriate HLA-molecule, as well as treatment with IFNγ, prior to each T 
cell assay. Interestingly, the co-transfection optimisation to find an appropriate DNA 
concentration for T cell recognition demonstrated that while EBNA1 concentration was always 
the limiting factor for T cell recognition, increasing the concentration of HLA-encoding plasmid 




both cell types tested. This is most likely due to the increased levels of toxicity from higher 
concentrations of DNA reducing cell viability [59], therefore leading to less transfected cells 
being present to stimulate T cells.    
 
A CD4 T cell clone specific to the epitope VYG (an autophagy independent epitope from 
nuclear-localised EBNA1) was used to test the recognition of the epithelial and MJS cell lines, 
transfected with plasmids encoding different EBNA1 variants. The results showed that the 
recognition of these cell lines followed the same pattern as in LCLs (shown by a previous 
publication [45]); low levels of T cell recognition for the nuclear EBNA1 that increased for the 
cytoplasmic and was substantially higher for the invariant-chain variant. This was followed by the 
maximum possible stimulation of the T cell by the cell line that had been pulsed with the cognate 
peptide. While this pattern was followed by the HeLa and MJS cell lines, a notable exception 
was seen in both gastric carcinoma cell lines, MKN1 and MKN28, where the T cell recognition of 
cytoplasmic-EBNA1 was equal to or lower than recognition levels of the nuclear variant. In 
earlier protein stability assays both gastric carcinoma cell lines displayed very high levels of 
cytoplasmic-EBNA1 stability, which was indistinguishable from the stable nuclear EBNA1. It 
would therefore be interesting to compare the stability of cytoplasmic-EBNA1 in the other 
epithelial cell lines, with higher levels of cytoplasmic-EBNA1 recognition in future work.  
 
A CD4 T cell clone specific to the epitope SNP (an autophagy dependent epitope from nuclear 
EBNA1) was used to test the recognition of the MJS and all but one of the epithelial cell lines, 
transfected with plasmids encoding different EBNA1 variants. Again, the results showed that the 
recognition of these cell lines followed the same pattern as in LCLs (shown by a previous 
publication (Leung)); low levels of T cell recognition for the nuclear EBNA1 that increased for the 




were pulsed with the cognate peptide for SNP did not exhibit the maximum recognition levels, as 
IFNγ levels were consistently lower than the response to the transfected IiE1Δ variant. The 
mechanism for this pattern, seen consistently across multiple experiments, was unclear. The 
cognate peptide itself was validated by the good levels of T cell recognition of the peptide pulsed 
HLA matched LCL control. Potentially, the transfected HLA-DR51 was capable of functioning 
correctly with the presentation of endogenous proteins, but for unknown reasons was not fully 
responsive to peptide pulsing. The data could also suggest that the endogenous antigen 
processing pathway is actually manipulating the final epitope, which resulted in greater levels of 
T cell stimulation compared to the pulsed peptide. This could possibly come from alterations 
being made to the variable peptide flanking residues (PFRs). PFRs extend from the N- and C-
terminus of the MHC class II binding groove; whilst the core 9 amino acids remain unchanged, 
the PFR can be altered during the endogenous processing of antigens and there is evidence 
that this modulation will enhance CD4 T cell responses [60]. This phenomenon may therefore 
explain why the endogenously processed SNP peptide appears to give a stronger T cell 
response than the un-processed peptide used for pulsing cell. Another conceivable cause of this 
could have been an unknown factor affecting the cell lines used, although this seems unlikely as 
peptide pulsing worked in the same cell lines for the previous experiment with the transfected 
HLA-DR11. In this experiment it was also noticeable that the MJS cell line had much higher 
levels of SNP T cell recognition for cytoplasmic-EBNA1, including a ratio of cytoplasmic to 
invariant-chain IiE1Δ, in comparison to the epithelial cell lines. The mechanism of differential 
processing pathways of SNP and VYG from cytoplasmic-EBNA1 in the gastric carcinoma cell 
line was not explored further, but as it is different to B cells this could form the basis of future 






4.2.2 The effect of EBV-encoded miRNA on autophagy and CD4 T cell recognition 
Small non-coding RNA sequences, known as miRNAs, are able to regulate protein expression 
by binding to complementary sections of miRNA. In its latent phase, EBV expresses many 
miRNAs that affect the host cell’s expression profile, including some that have oncogenic 
properties such as enhancing a cell’s propensity for immortalisation [61]. Recent preliminary 
research has suggested that EBV-encoded miRNA, BART 18, contributes to suppressing 
autophagy within the host cells (E. Wiertz University of Leiden, personal communication). In 
theory, this would give a selective benefit to EBV by limiting the processing and therefore 
presentation of certain autophagy dependent epitopes of EBNA1 to CD4 T cells. To test this 
hypothesis, I collaborated with Wiertz’s laboratory, which provided me with two cell lines; an 
EBV-negative melanoma cell line (MJS) and an EBV-positive Burkitt lymphoma cell line (Jijoye). 
The Jijoye cell line, which had previously been shown to express the BART 18 miRNA using m-
R sensors, had been manipulated through lentiviral transduction and positive selection to 
generate three sub-lines expressing different plasmids that knocked out the function of particular 
miRNAs: Empty vector (EV) k/o as a negative control, BART 16 (B16) k/o as an extra negative 
control (although it could theoretically be possible for this miRNA to have an unknown role that 
could affect either autophagy or antigen presentation) and BART 18 (B18) k/o. As a 
complementary strategy an MJS cell line, which would be used to study the miRNA expression 
in isolation from the rest of the EBV genome, had been subjected to lentiviral transduction and 
positive selection to generate four sub-lines expressing different plasmids overexpressing 
miRNAs: EV overexpression, B16 overexpression, B18 overexpression and Cluster 1 (C1) 
overexpression (which contained BART 18-21). Within these two systems, loss of function and 






The analysis of autophagy levels in the MJS sub-lines, overexpressing vectors (EV, B16, B18 or 
C1), demonstrated that all lines had basal levels of autophagy under normal conditions. 
However, both sub-lines overexpressing B18 (B18 and C1) had higher basal autophagy levels in 
comparison to the negative controls (EV and B16 overexpression sub-lines). With the 
overexpression of BART 18 resulting in increased autophagy levels, my data entirely 
contradicted the original hypothesis from the Wiertz laboratory. 
  
The analysis of autophagy levels in the Jijoye cell lines, expressing various miRNA k/o vectors 
(EV, B16 or B18), demonstrated that all of the lines had basal levels of autophagy. Under normal 
conditions, low levels of autophagy were seen for the B16 k/o sub-line, while higher levels of 
autophagy were seen for the EV k/o and B18 k/o sub-lines, where the autophagy levels were 
equivalent. Again, this result did not support the original hypothesis. Interestingly upon serum 
starvation, the autophagy levels in the B18 k/o sub-line increased, whereas the autophagy levels 
in both the B16 k/o and EV k/o sub-lines (where B18 was still functionally expressed) were 
slightly reduced in comparison to the basal levels. This suggests that BART 18 only acts to 
downregulate autophagy in times of physiological stress, such as starvation. The data from the 
previous experiment, in which B18 was overexpressed in MJS cells, does not correlate with this 
result. It could however be possible that multiple factors are required to see this effect, implying 
that removing B18 affects the pathway but expressing it alone is not sufficient to trigger the 
mechanism. Multiple miRNAs can be required to co-regulate certain functions, a phenomenon 
known as miRNA synergy [62]. This hypothesis of BART 18 and unknown factors requires 
further investigation. 
 
After documenting the effect of the miRNAs on autophagy levels, T cell recognition of the 




the various EBNA1 constructs (discussed previously) were shown to have equivalent recognition 
of (autophagy dependent) epitope SNP from a CD4 T cell assay, with several exceptions. The 
key result was that no difference was observed in the B18 overexpression sub-line compared to 
the EV or B16 overexpression sub-lines. Interestingly, in comparison to the other sub-lines, C1 
overexpression recognition levels were lower for E1ΔGA, IiE1Δ and peptide pulsed cells and the 
response to the peptide pulsed B18 overexpression sub-line was substantially higher. In order to 
confirm these results, these experiments will need to be replicated.     
 
The Jijoye sub-lines expressing the various miRNA k/o vectors were used to compare the 
natural recognition of MHC class II epitopes VYG (autophagy independent) and SNP (autophagy 
dependent) to establish whether B18 k/o would affect CD4 T cell recognition. In comparison to 
the the negative controls (EV k/o and B16 k/o), the B18 k/o sub-line showed a 0.5 fold increase 
in IFNγ for SNP T cell recognition and a 0.2 fold increase for VYG T cell recognition. It is worth 
noting that the Jijoye cell lines pulsed with the cognate peptide for VYG gave very low levels of T 
cell recognition, especially in the case of the EV k/o line, when compared to the other two sub-
lines. The VYG T cell clone was originally isolated from a Caucasian donor and had previously 
been shown to recognise DR11 restricted cells from an Asian donor of a different DR11 subtype. 
The Jijoye cell line was established from an African child with Burkitt's lymphoma and was 
therefore likely to carry a different subtype of DR11 which may exhibit a reduced ability to 
stimulate this VYG T cell clone. This may explain why the peptide pulsing for the Jijoye cell line 
proved to be very inefficient for VYG T cell recognition. From these results it is difficult to form a 
solid conclusion, as the IFNγ production in response to the physiological levels of EBNA1 
expressed by the Jijoye sub-lines was relatively low and the 0.5 fold increase in IFNγ levels was 
therefore only a relatively small absolute change (approximately 50pg/ml). To explore whether 




nuclear EBNA1 in the Jijoye sublines, as this would increase the T cell recognition levels but not 









4.3 EBNA1 Inhibition  
The goal of immunotherapeutic treatment is to create an immune response against a given 
target. One way to do this is by manipulating the effector cells (activating or introducing specific 
T cells), while another possibility is to manipulate the target cells to make them more visible to 
the immune system. In the context of altering EBV infected cells, introducing dominant-negative 
EBNA1 proteins has been shown to alter EBNA1 processing, resulting in increased levels of 
MHC class I presentation and enhanced levels of T cell recognition [52]. Unfortunately, technical 
limitations make the clinical application of these proteins currently unfeasible. A more realistic 
treatment option could arise from the use of small peptides as pharmacological inhibitors of 
EBNA1 dimerisation, which are currently being developed by several groups [54]. Until now, 
pharmacological inhibition of EBNA1 dimerisation has not been investigated as a method of 
manipulating T cell recognition. 
 
4.3.1 The effect of JLP2 EBNA1 inhibition on CD4 T cell recognition  
JLP2 is a fluorescent EBNA1 dimerisation inhibitor that has been shown to selectively visualise 
and reduce the viability of an EBV-positive NPC cell line in vitro [55]. The collaborating 
laboratory (G. Wong, Hong Kong Baptist University) provided me with both JLP1 and JLP2 
peptides for use in experiments exploring their specific effects on visualisation, viability and CD4 
T cell recognition of EBV-positive cell lines. 
 
The initial experiment I conducted attempting to replicate the specific visualisation of EBNA1 
was unsuccessful in showing a clear distinction between EBV-positive and negative cell lines 
treated with JLP1 or JLP2. The results demonstrated that both peptides have non-specific 
binding (despite numerous washes) and fluorescence (even in the absences of cells) which 




promising results were obtained using the quantifiable method of flow cytometry analysis, where 
it was possible to gate exclusively on cells by forward/side scatter analysis. Here, a small but 
observable increase in fluorescence intensity was seen for EBV-positive LCLs (B cells), but not 
for the EBV-negative B cells treated with JLP2 (20µM). Lower doses of JLP2 (5µM) were not 
sufficient to induce the increase in fluorescence for either of the EBV-positive LCLs. This result 
indicated that high concentrations of JLP2 are required to generate observable detection of 
EBV-positive B cell lines. These fluorescence intensity increases for LCLs appear to be smaller 
in comparison to the results of the previously published data that treated EBV-positive NPC cell 
lines with JLP2 [55]. This could potentially indicate different levels of EBNA1 expression or 
different levels of JLP2 internalisation for various cell lines. Future development of EBNA1 
inhibitors will need to focus on achieving efficient internalisation of peptides to effectively inhibit 
EBNA1 at low doses.  
 
In the previous publication reporting JLP2, the EBV-positive NPC (C666.1) and EBV-negative 
epithelial (HeLa) cell lines treated with the compound originated from different backgrounds. 
Although promising preliminary data was produced, the effect of JLP2 on cell viability cannot be 
critically assessed as it is not known whether these very different cell types would respond 
differently to the peptide treatment, regardless of EBV infection status. For this study I therefore 
chose four B cell lines, two EBV-positive and two EBV-negative, to compare cell viability upon 
treatment with JLP2 in similar cell backgrounds. A WST-1 (cell proliferation) assay demonstrated 
a JLP2 dose dependent negative effect on the cell viability for one of the EBV-positive B cells 
(LCL (GT)). However, this effect was only transitory, with the impact on cell viability seen at 4 
hours, reduced after 24h and lost after 48h. While it does not appear as though the JLP2 
detrimentally affected EBV-negative lines, it also did not affect the cell viability of the second 




which was shown to have the greater increase in MFI (shown in the last experiment) compared 
to LCL (GS), indicating that the former has higher levels of JLP2 internalisation. This difference 
in JLP2 internalisation may account for the differences in viability observed. This experiment still 
requires replication in order to validate the result. However, these results from LCL (GT) do not 
contradict the previously published data, in which an NPC cell line displayed a JLP2 dose 
dependent cell viability reduction 12h after treatment and no long term effects of JLP2 treatment 
were shown. A mechanism explaining why an EBNA1 inhibitor would cause such an immediate 
yet transitory effect on cell viability is unknown; potentially, cells are reliant on the presence of 
functional EBNA1 to administer its known effects on cell immortalisation and removing EBNA1 
may therefore sensitise cells to apoptosis. The long term treatment with specific EBNA1 DNA 
binding inhibitors leads to the gradual removal of the EBV episome from cells as they divide, 
retarding the growth of EBV-positive cells (in comparison to EBV-negative cell growth). 
However, this process takes six to seven days before producing a noticeable difference [63]. 
EBNA1 dimerisation inhibition with JLP2 may potentially have the same long term impact. 
However, this requires further investigation. 
 
Finally, I was interested in exploring the effect of EBNA1 dimerisation inhibition on epitope 
presentation to CD4 T cells, given that the inhibition of dimerisation could potentially increase 
protein degradation levels. The results here demonstrated that for both autophagy dependent 
and independent epitopes, only a very slight increase in CD4 T cell recognition of LCLs was 
seen upon treatment with JLP2 and that this effect was not dose dependent. From this data, it 
can be concluded that it is unlikely that the 72h treatment with JLP2 had a significant effect on 
the antigen processing and presentation of EBNA1 by MHC class II. Future work could 
investigate this in other cell types such as EBV-positive epithelial cells and could also explore 




4.4 Final discussion and future work 
 
In this study I demonstrated that supraphysiological levels of both nuclear and cytoplasmic-
EBNA1 were stable in the transfected epithelial cell lines that possessed high levels of basal 
autophagy. This contradicts a previous report published by Tellam et al. regarding epithelial 
cells, but is in accordance with the previous data exploring EBNA1 stability in B cells. My results 
go on to show that epithelial cells, once treated with IFNγ, were also similar to B cells in terms of 
EBNA1 epitope presentation to CD4 T cells. In B cells, CD4 T cell recognition of EBNA1 variants 
(with different abilities to access the MHC class II processing system) shows a hierarchy, which 
is maintained in epithelial cells (with a few exceptions). The low levels of EBNA1 degradation are 
nevertheless sufficient to elicit CD4 T cell recognition of epithelial cells as well as B cells. The 
expression of miRNA BART 18 k/o in an EBV-positive B cell line appears to slightly improve the 
recognition of autophagy dependent EBNA1 epitopes by CD4 T cells. However, the data from 
measuring autophagy levels suggests that the BART 18 only suppresses the increase in 
autophagy levels brought about by serum starvation. The results from an EBV-negative cell line 
overexpressing BART 18 did not reflect these results; it could therefore be possible that this 
mechanism requires multiple miRNA synergy. The treatment of cells with an EBNA1 inhibitor, 
JLP2, showed selective fluorescence in EBV-positive B cells, but did not greatly impact the level 
of T cell recognition. The treatment of B cells with JLP2 also showed an immediate yet transitory 
effect on cell viability and the inconsistence seen between EBV-positive cell lines may be 
explained by the different levels of drug uptake.   
 
This MRes project offers the first examination of the ability of EBNA1-specific CD4 T cells to 
recognise epithelial cells. Despite the low levels of EBNA1 degradation observed, it is important 




expressed by the EBV-positive gastric carcinoma cell line MKN28 (once transfected with the 
appropriate HLA-molecule to match the CD4 T cell and treated with IFNγ to upregulate MHC 
class II presentation). This result shows that naturally expressed by EBNA1 can be present on 
the cell surface and could therefore be a potential target for immunotherapy in a clinical setting, 
although more sensitive T cell effectiveness would likely be required to elicit high levels of T cell 
recognition. Such effectors have recently been generated (C. Munz, personal communication) 
and future work using such cells could investigate the mechanisms of how different EBNA1 
epitopes are processed and presented. Through studying the different epitope processing 
mechanisms, this research could determine the importance of autophagy or other endogenous 
pathways. Furthermore, higher avidity effector cells could be used to assess the role of various 
miRNAs, such as BART 18, on the manipulation of antigen processing and presentation, as the 
present data suggests that multiple factors may act in synergy to affect certain autophagy 
pathways. Given that different cell types appear to vary in their uptake of JLP2, it may be that 
epithelial lineages are more sensitive to this compound than B cell malignancies, especially as 
the original work on JLP2 treatment of NPC lines yielded promising results. Future work could 
therefore investigate the treatment of various EBV-positive and negative gastric carcinoma with 
EBNA1 dimerisation inhibitors for the immunotherapy of EBV-associated malignancies. Given 
that the majority of EBV-positive malignancies are of epithelial origin, exploring the factors that 











Table S3.1.1 Data from the comparison of transfection reagents in epithelial cell lines    
The reagents Lipofectamine 2000 or Mirus Transit X2 were used to transfect the cell lines 
(MKN1, MKN28, MKN45, NUGC4, HeLa, 293FT and HaCaT) with 4µg/ml pCDNA3-GFP. Flow 
cytometry was used to assess transfection efficiency (GFP expression) and cell viability 
(propidium iodide staining), using mock transfected cells as a baseline reference point. Intact 
cells were analysed by gating on this population using forward scatter and side scatter (not 
shown). The results demonstrate that the cell viability was generally high (between 80-100%) for 
both reagents, but Lipofectamine transfections were consistently better, or as good as Muris 
















Table S3.2.1 Data from the analysis of HLA restriction T cell assay for epithelial cell lines   
The cell lines (Hela, HaCaT, 293FT, MKN1, MKN28 and MKN45) were incubated with IFNγ for 
72h to induce the expression of MHC class II. The cells were then peptide pulsed with each T 
cell clone’s cognate peptide. A T cell assay was then performed and IFNγ release was 

















Table S3.2.2 Summary of miRNA k/o and overexpression effect on autophagy 
Data summarised from LC3 fluxes, comparing the levels of autophagy seen in empty vector 









Figure S3.2.1 IFNγ   Cell surface staining for MHC class I and II presentation, varying IFNγ 
concentrations, in Jijoye and MJS cell lines 
FAC analysis of MHC class I and II surface presentation in the Jijoye (right column)  and MJS 
(left column) cell line, cultured for 72h in different levels of IFNγ (0,10,100ng/ml). The result 
shows that Jijoye’s MHC class I and II is not upregulated and that there is no additional 









Figure S4.1.1 Analysis of E1ΔGA stability in transfected HaCaT cell lines  
The HaCaT cell line was transfected with pCDNA3-E1ΔGA (4ng/ml) and cultured for 48h. 
Protein synthesis was then inhibited with the addition of cycloheximide (50ug/ml) and cells were 
chased for 0, 4, 8 and 24h. Samples were standardised and EBNA1 levels were assessed using 
western blotting. The consistent band intensity shown across 24h, except for the anomaly at 4h, 
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